Maryland 2022 Regular Session

Maryland House Bill HB33 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
2	1
3		-	– 1 –
4		-	Chapter 285
5		-	(House Bill 33)
6	2
7		-	AN ACT concerning
	3	+	EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
	4	+	[Brackets] indicate matter deleted from existing law.
	5	+	Underlining indicates amendments to bill.
	6	+	Strike out indicates matter stricken from the bill by amendment or deleted from the law by
	7	+	amendment.
	8	+	hb0033
8	9
9		-	Criminal Law – Controlled Dangerous Substances – Schedules – Adjustment
	10	+	HOUSE BILL 33
	11	+	E1 2lr1215
	12	+	(PRE–FILED) CF SB 614
	13	+	By: Delegate Shetty
	14	+	Requested: November 1, 2021
	15	+	Introduced and read first time: January 12, 2022
	16	+	Assigned to: Judiciary
	17	+	Committee Report: Favorable
	18	+	House action: Adopted
	19	+	Read second time: March 7, 2022
10	20
11		-	FOR the purpose of repealing certain lists of substances designated as controlled dangerous
12		-	substances under certain schedules under the Maryland Controlled Substances Act;
13		-	and generally relating to schedules of controlled dangerous substances.
	21	+	CHAPTER ______
14	22
15		-	BY repealing and reenacting, with amendments,
16		-	Article – Criminal Law
17		-	Section 5–101(z) through (dd) and 5–402 through 5–406
18		-	Annotated Code of Maryland
19		-	(2021 Replacement Volume and 2021 Supplement)
	23	+	AN ACT concerning 1
20	24
21		-	BY repealing and reenacting, without amendments,
22		-	Article – Criminal Law
23		-	Section 5–202(a), (b), and (f)
24		-	Annotated Code of Maryland
25		-	(2021 Replacement Volume and 2021 Supplement)
	25	+	Criminal Law – Controlled Dangerous Substances – Schedules – Adjustment 2
26	26
27		-	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
28		-	That the Laws of Maryland read as follows:
	27	+	FOR the purpose of repealing certain lists of substances designated as controlled dangerous 3
	28	+	substances under certain schedules under the Maryland Controlled Substances Act; 4
	29	+	and generally relating to schedules of controlled dangerous substances. 5
29	30
30		-	Article – Criminal Law
	31	+	BY repealing and reenacting, with amendments, 6
	32	+	Article – Criminal Law 7
	33	+	Section 5–101(z) through (dd) and 5–402 through 5–406 8
	34	+	Annotated Code of Maryland 9
	35	+	(2021 Replacement Volume and 2021 Supplement) 10
31	36
32		-	5–101.
	37	+	BY repealing and reenacting, without amendments, 11
	38	+	Article – Criminal Law 12
	39	+	Section 5–202(a), (b), and (f) 13
	40	+	Annotated Code of Maryland 14
	41	+	(2021 Replacement Volume and 2021 Supplement) 15
33	42
34		-	~~(z) “Schedule~~ ~~I” means [a~~ ~~list of]~~ THE ~~controlled dangerous substances [that~~
35		-	~~appears] DESCRIBED in § 5–402~~ of ~~this title.~~
	43	+	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 16
	44	+	That the Laws of Maryland read as follows: 17
36	45
37		-	(aa) “Schedule II” means [a list of] THE controlled dangerous substances [that
38		-	appears] DESCRIBED in § 5–403 of this title.
	46	+	Article – Criminal Law 18
39	47
40		-	(bb) “Schedule III” means [a list of] THE controlled dangerous substances [that
41		-	appears] DESCRIBED in § 5–404 of this title.
	48	+	5–101. 19 2 HOUSE BILL 33
42	49
43		-	(cc) “Schedule IV” means [a list of] THE controlled dangerous substances [that
44		-	appears] DESCRIBED in § 5–405 of this title.
45	50
46		-	(dd) “Schedule V” means [a list of] THE controlled dangerous substances [that
47		-	appears] DESCRIBED in § 5–406 of this title.
48		-	Ch. 285 2022 LAWS OF MARYLAND
49	51
50		-	~~– 2 –~~
51		-	5–~~202~~.
	52	+	(z) “Schedule I” means [a list of] THE controlled dangerous substances [that 1
	53	+	appears] DESCRIBED in § 5–402 of this title. 2
52	54
53		-	(a) The Department shall control all substances listed in Subtitle 4 of this title.
	55	+	(aa) “Schedule II” means [a list of] THE controlled dangerous substances [that 3
	56	+	appears] DESCRIBED in § 5–403 of this title. 4
54	57
55		-	(b) In accordance with the Administrative Procedure Act, the Department may
56		-	add a substance as a controlled dangerous substance on its own initiative or on the petition
57		-	of an interested party.
	58	+	(bb) “Schedule III” means [a list of] THE controlled dangerous substances [that 5
	59	+	appears] DESCRIBED in § 5–404 of this title. 6
58	60
59		-	(f) (1) A new substance that is designated as a controlled substance under
60		-	federal law is a similarly controlled dangerous substance under this title unless the
61		-	Department objects to the inclusion.
	61	+	(cc) “Schedule IV” means [a list of] THE controlled dangerous substances [that 7
	62	+	appears] DESCRIBED in § 5–405 of this title. 8
62	63
63		-	(2) If the ~~Department objects,~~ ~~it shall publish the reasons for the objection~~
64		-	~~and give each interested party an opportunity to be heard~~.
	64	+	(dd) “Schedule V” means [a list of] THE controlled dangerous substances [that 9
	65	+	appears] DESCRIBED in § 5–406 of this title. 10
65	66
66		-	(3) After the hearing, the Department shall publish its decision, which is
67		-	final.
	67	+	5–202. 11
68	68
69		-	(4) An action for judicial review of a final decision made in accordance with
70		-	this section does not stay the effect of the decision.
	69	+	(a) The Department shall control all substances listed in Subtitle 4 of this title. 12
71	70
72		-	5–402.
	71	+	(b) In accordance with the Administrative Procedure Act, the Department may 13
	72	+	add a substance as a controlled dangerous substance on its own initiative or on the petition 14
	73	+	of an interested party. 15
73	74
74		-	(a) Schedule I consists of each [controlled dangerous substance]:
	75	+	(f) (1) A new substance that is designated as a controlled substance under 16
	76	+	federal law is a similarly controlled dangerous substance under this title unless the 17
	77	+	Department objects to the inclusion. 18
75	78
76		-	(1) ~~[listed in]~~ ~~CONTROLLED DANGEROUS SUBSTANCE ANALOGUE~~ , AS
77		-	~~DEFINED IN SUBSECTIO N (B) OF this section;~~
	79	+	(2) If the Department objects, it shall publish the reasons for the objection 19
	80	+	and give each interested party an opportunity to be heard. 20
78	81
79		-	(2) ~~CONTROLLED DANGEROUS SUBSTANCE added to Schedule I by~~ the
80		-	~~Department under § 5–202(b) of this title; [or] AND~~
	82	+	(3) After the hearing, the Department shall publish its decision, which is 21
	83	+	final. 22
81	84
82		-	(3) CONTROLLED DANGEROUS SUBSTANCE designated as a Schedule I
83		-	controlled dangerous substance by the federal government unless the Department objects
84		-	under § 5–202(f) of this title.
	85	+	(4) An action for judicial review of a final decision made in accordance with 23
	86	+	this section does not stay the effect of the decision. 24
85	87
86		-	[(b) Unless specifically excepted under this subtitle or listed in another schedule,
87		-	any of the following opiates, including their isomers, including optical and geometric
88		-	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the
89		-	existence of such isomers, esters, ethers, or salts is possible within the specific chemical
90		-	designation, are substances listed in Schedule I:
	88	+	5–402. 25
91	89
92		-	(1) acetyl–alpha–methylfentanyl (N –[1–(1–methyl–2–phenethyl)–4–
93		-	piperidinyl]–N–phenylacetamide);
	90	+	(a) Schedule I consists of each [controlled dangerous substance]: 26
94	91
95		-	(2) acetylmethadol; LAWRENCE J. HOGAN, JR., Governor Ch. 285
	92	+	(1) [listed in] CONTROLLED DANGEROUS SUBSTANCE ANALOGUE , AS 27
	93	+	DEFINED IN SUBSECTIO N (B) OF this section; 28
96	94
97		-	– 3 –
	95	+	(2) CONTROLLED DANGEROUS SUBSTANCE added to Schedule I by the 29
	96	+	Department under § 5–202(b) of this title; [or] AND 30 HOUSE BILL 33 3
98	97
99		-	(3) acetyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacetamide);
100	98
101		-	(4) Acryl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacrylamide;
102	99
103		-	(5) AH–7921 (3,4–dichloro–N–[(1–dimethylamino) cyclohexylmethyl])
104		-	benzamide;
	100	+	(3) CONTROLLED DANGEROUS SUBSTANCE designated as a Schedule I 1
	101	+	controlled dangerous substance by the federal government unless the Department objects 2
	102	+	under § 5–202(f) of this title. 3
105	103
106		-	(6) allylprodine;
	104	+	[(b) Unless specifically excepted under this subtitle or listed in another schedule, 4
	105	+	any of the following opiates, including their isomers, including optical and geometric 5
	106	+	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the 6
	107	+	existence of such isomers, esters, ethers, or salts is possible within the specific chemical 7
	108	+	designation, are substances listed in Schedule I: 8
107	109
108		-	(7) alphacetylmethadol, except levo–alphacetylmethadol;
	110	+	(1) acetyl–alpha–methylfentanyl (N –[1–(1–methyl–2–phenethyl)–4–9
	111	+	piperidinyl]–N–phenylacetamide); 10
109	112
110		-	(8) ~~alphameprodine~~;
	113	+	(2) acetylmethadol; 11
111	114
112		-	(9) ~~alphamethadol~~;
	115	+	(3) acetyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacetamide); 12
113	116
114		-	(10) alpha–methylfentanyl (N–[1–(alpha–methyl–beta–phenyl)ethyl–4–
115		-	piperidyl] propionanilide; 1–(1–methyl–2–phenylethyl)–4–(N–propanilido) piperidine);
	117	+	(4) Acryl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylacrylamide; 13
116	118
117		-	(11) ~~alpha~~–~~methylthiofentanyl~~ (N –[1–~~methyl–2–(2–thienyl~~)~~ethyl–4–~~
118		-	~~piperidinyl]–N–phenylpropanamide)~~;
	119	+	(5) AH–7921 (3,4–dichloro–N–[(1–dimethylamino) cyclohexylmethyl]) 14
	120	+	benzamide; 15
119	121
120		-	(12) ~~benzethidine~~;
	122	+	(6) allylprodine; 16
121	123
122		-	(13) ~~betacetylmethadol~~;
	124	+	(7) alphacetylmethadol, except levo–alphacetylmethadol; 17
123	125
124		-	(14) beta–hydroxyfentanyl (N –[1–(2–hydroxy–2–phenethyl)–4–
125		-	piperidinyl]–N–phenylpropanamide);
	126	+	(8) alphameprodine; 18
126	127
127		-	(15) ~~beta–hydroxy–3–methylfentanyl~~;
	128	+	(9) alphamethadol; 19
128	129
129		-	(16) N–[1–[2–~~hydroxy~~–2–~~(thiophen–2–yl~~)ethyl~~]piperidin~~–4–~~yl]–N–~~
130		-	~~phenylpropionamide~~;
	130	+	(10) alpha–methylfentanyl (N–[1–(alpha–methyl–beta–phenyl)ethyl–4–20
	131	+	piperidyl] propionanilide; 1–(1–methyl–2–phenylethyl)–4–(N–propanilido) piperidine); 21
131	132
132		-	(17) betameprodine;
	133	+	(11) alpha–methylthiofentanyl (N –[1–methyl–2–(2–thienyl)ethyl–4–22
	134	+	piperidinyl]–N–phenylpropanamide); 23
133	135
134		-	(18) ~~betamethadol~~;
	136	+	(12) benzethidine; 24
135	137
136		-	(19) ~~betaprodine~~;
	138	+	(13) betacetylmethadol; 25
137	139
138		-	(20) ~~butyryl fentanyl~~ (N –(1–~~phenethylpiperidin~~–4–~~yl)–N–~~
139		-	~~phenylbutyramide~~);
	140	+	(14) beta–hydroxyfentanyl (N –[1–(2–hydroxy–2–phenethyl)–4–26
	141	+	piperidinyl]–N–phenylpropanamide); 27
140	142
141		-	(21) clonitazene;
	143	+	(15) beta–hydroxy–3–methylfentanyl; 28
	144	+	4 HOUSE BILL 33
142	145
143		-	(22) dextromoramide; Ch. 285 2022 LAWS OF MARYLAND
144	146
145		-	– 4 –
	147	+	(16) N–[1–[2–hydroxy–2–(thiophen–2–yl)ethyl]piperidin–4–yl]–N–1
	148	+	phenylpropionamide; 2
146	149
147		-	(23) ~~diampromide~~;
	150	+	(17) betameprodine; 3
148	151
149		-	(24) ~~diethylthiambutene~~;
	152	+	(18) betamethadol; 4
150	153
151		-	(25) ~~difenoxin~~;
	154	+	(19) betaprodine; 5
152	155
153		-	(26) dimenoxadol;
	156	+	(20) butyryl fentanyl (N –(1–phenethylpiperidin–4–yl)–N–6
	157	+	phenylbutyramide); 7
154	158
155		-	(27) ~~dimepheptanol~~;
	159	+	(21) clonitazene; 8
156	160
157		-	(28) ~~dimethylthiambutene~~;
	161	+	(22) dextromoramide; 9
158	162
159		-	(29) ~~dioxaphetyl butyrate~~;
	163	+	(23) diampromide; 10
160	164
161		-	(30) ~~dipipanone~~;
	165	+	(24) diethylthiambutene; 11
162	166
163		-	(31) ~~ethylmethylthiambutene~~;
	167	+	(25) difenoxin; 12
164	168
165		-	(32) ~~etonitazene~~;
	169	+	(26) dimenoxadol; 13
166	170
167		-	(33) ~~etoxeridine~~;
	171	+	(27) dimepheptanol; 14
168	172
169		-	(34) 4–Fluoroisobutyryl fentanyl (N –(4–fluorophenyl)–N–(1–
170		-	phenethylpiperidin–4–yl)isobutyramide;
	173	+	(28) dimethylthiambutene; 15
171	174
172		-	(35) furanyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylfuran–2–
173		-	carboxamide);
	175	+	(29) dioxaphetyl butyrate; 16
174	176
175		-	(36) ~~furethidine~~;
	177	+	(30) dipipanone; 17
176	178
177		-	(37) ~~hydroxypethidine~~;
	179	+	(31) ethylmethylthiambutene; 18
178	180
179		-	(38) ~~ketobemidone~~;
	181	+	(32) etonitazene; 19
180	182
181		-	(39) ~~levomoramide~~;
	183	+	(33) etoxeridine; 20
182	184
183		-	(40) levophenacylmorphan;
	185	+	(34) 4–Fluoroisobutyryl fentanyl (N –(4–fluorophenyl)–N–(1–21
	186	+	phenethylpiperidin–4–yl)isobutyramide; 22
184	187
185		-	(41) ~~3–methylfentanyl~~ (N–~~[3–methyl–~~1–~~(2–phenylethyl)~~–4–~~piperidyl]~~–N–
186		-	~~phenylpropanamide~~);
	188	+	(35) furanyl fentanyl (N–(1–phenethylpiperidin–4–yl)–N–phenylfuran–2–23
	189	+	carboxamide); 24
187	190
188		-	(42) ~~3–methylthiofentanyl~~;
	191	+	(36) furethidine; 25
189	192
190		-	(43) morpheridine;
191		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	193	+	(37) hydroxypethidine; 26 HOUSE BILL 33 5
192	194
193		-	– 5 –
194		-	(44) MPPP (1–methyl–4–phenyl–4–propionoxypiperidine);
195	195
196		-	(45) mt–45 (1–cyclohexyl–4–(1,2–diphenylethyl)piperazine);
197	196
198		-	(46) ~~noracymethadol~~;
	197	+	(38) ketobemidone; 1
199	198
200		-	(47) ~~norlevorphanol~~;
	199	+	(39) levomoramide; 2
201	200
202		-	(48) ~~normethadone~~;
	201	+	(40) levophenacylmorphan; 3
203	202
204		-	(49) norpipanone;
	203	+	(41) 3–methylfentanyl (N–[3–methyl–1–(2–phenylethyl)–4–piperidyl]–N–4
	204	+	phenylpropanamide); 5
205	205
206		-	(50) ocfentanil (N–(2–fluorophenyl)–2–methoxy–N–(1–phenethylpiperidin–
207		-	4–yl)acetamide);
	206	+	(42) 3–methylthiofentanyl; 6
208	207
209		-	(51) para–fluorofentanyl (N–(4–fluorophenyl)–N–[1–(2–phenethyl)–4–
210		-	piperidinyl] propanamide;
	208	+	(43) morpheridine; 7
211	209
212		-	(52) ~~PEPAP~~ (1–~~(–2–phenethyl)~~–4–phenyl–4–~~acetoxypiperidine~~);
	210	+	(44) MPPP (1–methyl–4–phenyl–4–propionoxypiperidine); 8
213	211
214		-	(53) ~~phenadoxone~~;
	212	+	(45) mt–45 (1–cyclohexyl–4–(1,2–diphenylethyl)piperazine); 9
215	213
216		-	(54) ~~phenampromide~~;
	214	+	(46) noracymethadol; 10
217	215
218		-	(55) ~~phenomorphan~~;
	216	+	(47) norlevorphanol; 11
219	217
220		-	(56) ~~phenoperidine~~;
	218	+	(48) normethadone; 12
221	219
222		-	(57) ~~piritramide~~;
	220	+	(49) norpipanone; 13
223	221
224		-	(58) proheptazine;
	222	+	(50) ocfentanil (N–(2–fluorophenyl)–2–methoxy–N–(1–phenethylpiperidin–14
	223	+	4–yl)acetamide); 15
225	224
226		-	(59) properidine;
	225	+	(51) para–fluorofentanyl (N–(4–fluorophenyl)–N–[1–(2–phenethyl)–4–16
	226	+	piperidinyl] propanamide; 17
227	227
228		-	(60) ~~propiram~~;
	228	+	(52) PEPAP (1–(–2–phenethyl)–4–phenyl–4–acetoxypiperidine); 18
229	229
230		-	(61) ~~racemoramide~~;
	230	+	(53) phenadoxone; 19
231	231
232		-	(62) tetrahydrofuranyl fentanyl (N –(1–phenethylpiperidin–4–yl)–N–
233		-	phenyltetrahydrofuran–2–carboxamide);
	232	+	(54) phenampromide; 20
234	233
235		-	(63) ~~thiofentanyl~~;
	234	+	(55) phenomorphan; 21
236	235
237		-	(64) ~~tilidine~~;
	236	+	(56) phenoperidine; 22
238	237
239		-	(65) ~~trimeperidine~~; ~~and Ch. 285 2022 LAWS OF MARYLAND~~
	238	+	(57) piritramide; 23
240	239
241		-	~~– 6 –~~
	240	+	(58) proheptazine; 24
242	241
243		-	(66) U–47700 (3,4 –dichloro–N–[2–(dimethylamino)cyclohexyl]–N–
244		-	methylbenzamide).
	242	+	(59) properidine; 25 6 HOUSE BILL 33
245	243
246		-	(c) Unless specifically excepted under this subtitle or listed in another schedule,
247		-	any of the following opium derivatives, including their salts, isomers, and salts of isomers,
248		-	whenever the existence of such salts, isomers, or salts of isomers is possible within the
249		-	specific chemical designation, are substances listed in Schedule I:
250	244
251		-	(1) acetorphine;
252	245
253		-	(2) ~~acetyldihydrocodeine~~;
	246	+	(60) propiram; 1
254	247
255		-	(3) ~~benzylmorphine~~;
	248	+	(61) racemoramide; 2
256	249
257		-	(4) codeine methylbromide;
	250	+	(62) tetrahydrofuranyl fentanyl (N –(1–phenethylpiperidin–4–yl)–N–3
	251	+	phenyltetrahydrofuran–2–carboxamide); 4
258	252
259		-	(5) ~~codeine–N–oxide~~;
	253	+	(63) thiofentanyl; 5
260	254
261		-	(6) ~~cyprenorphine~~;
	255	+	(64) tilidine; 6
262	256
263		-	(7) ~~desomorphine~~;
	257	+	(65) trimeperidine; and 7
264	258
265		-	(8) dihydromorphine;
	259	+	(66) U–47700 (3,4–dichloro–N–[2–(dimethylamino)cyclohexyl]–N–8
	260	+	methylbenzamide). 9
266	261
267		-	(9) drotebanol;
	262	+	(c) Unless specifically excepted under this subtitle or listed in another schedule, 10
	263	+	any of the following opium derivatives, including their salts, isomers, and salts of isomers, 11
	264	+	whenever the existence of such salts, isomers, or salts of isomers is possible within the 12
	265	+	specific chemical designation, are substances listed in Schedule I: 13
268	266
269		-	(10) ~~etorphine (except hydrochloride salt)~~;
	267	+	(1) acetorphine; 14
270	268
271		-	(11) ~~heroin~~;
	269	+	(2) acetyldihydrocodeine; 15
272	270
273		-	(12) ~~hydromorphinol~~;
	271	+	(3) benzylmorphine; 16
274	272
275		-	(13) ~~methyldesorphine~~;
	273	+	(4) codeine methylbromide; 17
276	274
277		-	(14) ~~methyldihydromorphine~~;
	275	+	(5) codeine–N–oxide; 18
278	276
279		-	(15) ~~morphine methylbromide~~;
	277	+	(6) cyprenorphine; 19
280	278
281		-	(16) ~~morphine methylsulfonate~~;
	279	+	(7) desomorphine; 20
282	280
283		-	(17) ~~morphine–N–oxide~~;
	281	+	(8) dihydromorphine; 21
284	282
285		-	(18) ~~myrophine~~;
	283	+	(9) drotebanol; 22
286	284
287		-	(19) ~~nicocodeine~~; ~~LAWRENCE J. HOGAN, JR., Governor Ch. 285~~
	285	+	(10) etorphine (except hydrochloride salt); 23
288	286
289		-	~~– 7 –~~
	287	+	(11) heroin; 24
290	288
291		-	(20) ~~nicomorphine~~;
	289	+	(12) hydromorphinol; 25
292	290
293		-	(21) ~~normorphine~~;
	291	+	(13) methyldesorphine; 26 HOUSE BILL 33 7
294	292
295		-	(22) pholcodine; and
296	293
297		-	(23) thebacon.
298	294
299		-	(d) Unless specifically excepted under this subtitle or listed in another schedule,
300		-	any material, compound, mixture, or preparation that contains any quantity of the
301		-	following hallucinogenic substances, or that contains any of its salts, isomers, including
302		-	optical, position, and geometric isomers, or salts of isomers, whenever the existence of such
303		-	salts, isomers, or salts of isomers is possible within the specific chemical designation, is a
304		-	substance listed in Schedule I:
	295	+	(14) methyldihydromorphine; 1
305	296
306		-	(1) ~~alpha–ethyltryptamine~~;
	297	+	(15) morphine methylbromide; 2
307	298
308		-	(2) ~~4–bromo–2,5–dimethoxy–amphetamine~~;
	299	+	(16) morphine methylsulfonate; 3
309	300
310		-	(3) 4–~~bromo~~–~~2,5–dimethoxyphenethylamine~~;
	301	+	(17) morphine–N–oxide; 4
311	302
312		-	(4) ~~2,5–dimethoxyamphetamine~~;
	303	+	(18) myrophine; 5
313	304
314		-	(5) ~~2,5–dimethoxy–4–ethylamphetamine (DOET)~~;
	305	+	(19) nicocodeine; 6
315	306
316		-	(6) ~~2,5–dimethoxy–4–(n)–propylthiophenethylamine (2C–T–7)~~;
	307	+	(20) nicomorphine; 7
317	308
318		-	(7) ~~4–methoxyamphetamine (PMA)~~;
	309	+	(21) normorphine; 8
319	310
320		-	(8) ~~5–methoxy–3,4–methylenedioxy–amphetamine~~;
	311	+	(22) pholcodine; and 9
321	312
322		-	(9) ~~4–methyl–2,5–dimethoxy–amphetamine;~~
	313	+	(23) thebacon. 10
323	314
324		-	(10) 3,4–methylenedioxy amphetamine;
	315	+	(d) Unless specifically excepted under this subtitle or listed in another schedule, 11
	316	+	any material, compound, mixture, or preparation that contains any quantity of the 12
	317	+	following hallucinogenic substances, or that contains any of its salts, isomers, including 13
	318	+	optical, position, and geometric isomers, or salts of isomers, whenever the existence of such 14
	319	+	salts, isomers, or salts of isomers is possible within the specific chemical designation, is a 15
	320	+	substance listed in Schedule I: 16
325	321
326		-	(11) ~~3,4~~–~~methylenedioxymethamphetamine (MDMA)~~;
	322	+	(1) alpha–ethyltryptamine; 17
327	323
328		-	(12) 3,4–~~methylenedioxy~~–N–~~ethylamphetamine (MDA)~~;
	324	+	(2) 4–bromo–2,5–dimethoxy–amphetamine; 18
329	325
330		-	(13) ~~N–hydroxy–3,~~4–~~methylenedioxyamphetamine~~;
	326	+	(3) 4–bromo–2,5–dimethoxyphenethylamine; 19
331	327
332		-	(14) ~~3,4~~,5–~~trimethoxyamphetamine~~;
	328	+	(4) 2,5–dimethoxyamphetamine; 20
333	329
334		-	(15) 5–methoxy–N, N–dimethyltryptamine;
335		-	Ch. 285 2022 LAWS OF MARYLAND
	330	+	(5) 2,5–dimethoxy–4–ethylamphetamine (DOET); 21
336	331
337		-	– 8 –
338		-	(16) alpha–methyltryptamine (AMT);
	332	+	(6) 2,5–dimethoxy–4–(n)–propylthiophenethylamine (2C–T–7); 22
339	333
340		-	(17) ~~bufotenine~~;
	334	+	(7) 4–methoxyamphetamine (PMA); 23
341	335
342		-	(18) ~~diethyltryptamine (DET)~~;
	336	+	(8) 5–methoxy–3,4–methylenedioxy–amphetamine; 24
343	337
344		-	(19) ~~dimethyltryptamine (DMT)~~;
	338	+	(9) 4–methyl–2,5–dimethoxy–amphetamine; 25
345	339
346		-	(20) 5–~~methoxy–N, N–diisopropyltryptamine (5–MeO–DIPT)~~;
	340	+	(10) 3,4–methylenedioxy amphetamine; 26 8 HOUSE BILL 33
347	341
348		-	(21) ibogaine;
349	342
350		-	(22) lysergic acid diethylamide;
351	343
352		-	(23) ~~marijuana~~;
	344	+	(11) 3,4–methylenedioxymethamphetamine (MDMA); 1
353	345
354		-	(24) ~~mescaline~~;
	346	+	(12) 3,4–methylenedioxy–N–ethylamphetamine (MDA); 2
355	347
356		-	(25) ~~parahexyl~~–~~7374~~;
	348	+	(13) N–hydroxy–3,4–methylenedioxyamphetamine; 3
357	349
358		-	(26) peyote (meaning all parts of the plant presently classified botanically
359		-	as Lophophora williamsii lemaire, whether growing or not, the seeds thereof, any extract
360		-	from any part of such plant, and every compound, manufacture, salt, derivative, mixture,
361		-	or preparation of such plant, its seeds, or extracts);
	350	+	(14) 3,4,5–trimethoxyamphetamine; 4
362	351
363		-	(27) N–~~ethyl–3–piperidyl benzilate~~;
	352	+	(15) 5–methoxy–N, N–dimethyltryptamine; 5
364	353
365		-	(28) N–~~methyl–3–piperidyl benzilate~~;
	354	+	(16) alpha–methyltryptamine (AMT); 6
366	355
367		-	(29) ~~psilocybin~~;
	356	+	(17) bufotenine; 7
368	357
369		-	(30) ~~psilocyn~~;
	358	+	(18) diethyltryptamine (DET); 8
370	359
371		-	(31) ~~tetrahydrocannabinols~~;
	360	+	(19) dimethyltryptamine (DMT); 9
372	361
373		-	(32) ethylamine analog of phencyclidine (N –ethyl–1–
374		-	phenylcyclohexylamine);
	362	+	(20) 5–methoxy–N, N–diisopropyltryptamine (5–MeO–DIPT); 10
375	363
376		-	(33) pyrrolidine analog of phencyclidine (1–(1–phenylcyclohexyl)–
377		-	pyrrolidine);
	364	+	(21) ibogaine; 11
378	365
379		-	(34) thiophene analog of phencyclidine (1–[1–(2–thienyl)–cyclohexyl]–
380		-	piperidine);
	366	+	(22) lysergic acid diethylamide; 12
381	367
382		-	(35) 1–[1–(2–thienyl)cyclohexyl]pyrrolidine;
383		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	368	+	(23) marijuana; 13
384	369
385		-	– 9 –
386		-	(36) 4–methylmethcathinone (mephedrone);
	370	+	(24) mescaline; 14
387	371
388		-	(37) ~~3, 4~~–~~methylenedioxypyrovalerone (MDPV)~~;
	372	+	(25) parahexyl–7374; 15
389	373
390		-	(38) 2–(2,5–dimethoxy–4–ethylphenyl) ethanamine (2C–E);
	374	+	(26) peyote (meaning all parts of the plant presently classified botanically 16
	375	+	as Lophophora williamsii lemaire, whether growing or not, the seeds thereof, any extract 17
	376	+	from any part of such plant, and every compound, manufacture, salt, derivative, mixture, 18
	377	+	or preparation of such plant, its seeds, or extracts); 19
391	378
392		-	(39) 2–~~(2,5~~–~~dimethoxy~~–~~4–methylphenyl) ethanamine (2C–D)~~;
	379	+	(27) N–ethyl–3–piperidyl benzilate; 20
393	380
394		-	(40) 2–(4–~~chloro~~–~~2,5–dimethoxyphenyl) ethanamine (2C–C)~~;
	381	+	(28) N–methyl–3–piperidyl benzilate; 21
395	382
396		-	(41) ~~2–(4–iodo–2,5–dimethoxyphenyl) ethanamine (2C–I)~~;
	383	+	(29) psilocybin; 22
397	384
398		-	(42) ~~2–[4–(ethylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–2)~~;
	385	+	(30) psilocyn; 23
399	386
400		-	(43) 2–[4–(isopropylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–4);
	387	+	(31) tetrahydrocannabinols; 24
	388	+	HOUSE BILL 33 9
401	389
402		-	(44) 2–(2,5–dimethoxyphenyl) ethanamine (2C–H);
403	390
404		-	(45) 2–(2,5–dimethoxy–4–nitro–phenyl) ethanamine (2C–N);
	391	+	(32) ethylamine analog of phencyclidine (N –ethyl–1–1
	392	+	phenylcyclohexylamine); 2
405	393
406		-	(46) 2–(2,5–dimethoxy–4–(n)–propylphenyl) ethanamine (2C–P);
	394	+	(33) pyrrolidine analog of phencyclidine (1 –(1–phenylcyclohexyl)–3
	395	+	pyrrolidine); 4
407	396
408		-	(47) 3,4–methylenedioxy–N–methylcathinone (methylone);
	397	+	(34) thiophene analog of phencyclidine (1–[1–(2–thienyl)–cyclohexyl]–5
	398	+	piperidine); 6
409	399
410		-	(48) (1–pentyl–1H–indol–3–yl) (2,2,3,3–tetramethylcyclopropyl) methanone
411		-	(UR–144);
	400	+	(35) 1–[1–(2–thienyl)cyclohexyl]pyrrolidine; 7
412	401
413		-	(49) [1–(5–fluoro–pentyl)–1H–indol–3–yl](2,2,3,3–tetramethylcyclopropyl)
414		-	methanone (5–fluoro–UR–144, XLR11);
	402	+	(36) 4–methylmethcathinone (mephedrone); 8
415	403
416		-	(50) N–(1–adamantyl)–1–pentyl–1H–indazole–3–carboxamide (APINACA,
417		-	AKB48);
	404	+	(37) 3, 4–methylenedioxypyrovalerone (MDPV); 9
418	405
419		-	(51) ~~quinolin~~–8–~~yl 1–pentyl–1H–indole–3–carboxylate~~ (PB–22);
	406	+	(38) 2–(2,5–dimethoxy–4–ethylphenyl) ethanamine (2C–E); 10
420	407
421		-	(52) quinolin–8–yl 1–(5–fluoropentyl)–1H–indole–3–carboxylate (5–fluoro–
422		-	PB–22);
	408	+	(39) 2–(2,5–dimethoxy–4–methylphenyl) ethanamine (2C–D); 11
423	409
424		-	(53) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(4–fluorobenzyl)–1H–
425		-	indazole–3–carboxamide (AB–FUBINACA);
	410	+	(40) 2–(4–chloro–2,5–dimethoxyphenyl) ethanamine (2C–C); 12
426	411
427		-	(54) N–(1–amino–3, 3 –dimethyl–1–oxobutan–2–yl)–1–pentyl–1H–
428		-	indazole–3–carboxamide (ADB–PINACA);
	412	+	(41) 2–(4–iodo–2,5–dimethoxyphenyl) ethanamine (2C–I); 13
429	413
430		-	(55) 2–(4–iodo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine
431		-	(25I–NBOMe); Ch. 285 2022 LAWS OF MARYLAND
	414	+	(42) 2–[4–(ethylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–2); 14
432	415
433		-	– 10 –
	416	+	(43) 2–[4–(isopropylthio)–2,5–dimethoxyphenyl] ethanamine (2C–T–4); 15
434	417
435		-	(56) 2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine
436		-	(25C–NBOMe);
	418	+	(44) 2–(2,5–dimethoxyphenyl) ethanamine (2C–H); 16
437	419
438		-	(57) 2–(4–bromo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine
439		-	(25B–NBOMe);
	420	+	(45) 2–(2,5–dimethoxy–4–nitro–phenyl) ethanamine (2C–N); 17
440	421
441		-	(58) marijuana extract (meaning an extract containing one or more
442		-	cannabinoids that has been derived from any plant of the genus cannabis, other than the
443		-	separated resin, whether crude or purified, obtained from the plant);
	422	+	(46) 2–(2,5–dimethoxy–4–(n)–propylphenyl) ethanamine (2C–P); 18
444	423
445		-	(59) 4–~~methyl~~–N–~~ethylcathinone~~ (~~4–MEC~~);
	424	+	(47) 3,4–methylenedioxy–N–methylcathinone (methylone); 19
446	425
447		-	(60) 4–methyl–alpha–pyrrolidinopropiophenone (4–MePPP);
	426	+	(48) (1–pentyl–1H–indol–3–yl) (2,2,3,3–tetramethylcyclopropyl) methanone 20
	427	+	(UR–144); 21
448	428
449		-	(61) alpha–pyrrolidinopentiophenone (alpha–PVP);
	429	+	(49) [1–(5–fluoro–pentyl)–1H–indol–3–yl](2,2,3,3–tetramethylcyclopropyl) 22
	430	+	methanone (5–fluoro–UR–144, XLR11); 23
450	431
451		-	(62) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) butan–1–one (butylone);
	432	+	(50) N–(1–adamantyl)–1–pentyl–1H–indazole–3–carboxamide (APINACA, 24
	433	+	AKB48); 25
452	434
453		-	(63) 2–(methylamino)–1–phenylpentan–1–one (pentedrone);
	435	+	(51) quinolin–8–yl 1–pentyl–1H–indole–3–carboxylate (PB–22); 26
	436	+	10 HOUSE BILL 33
454	437
455		-	(64) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) pentan–1–one (pentylone);
456	438
457		-	(65) 4–fluoro–N–methylcathinone (flephedrone);
	439	+	(52) quinolin–8–yl 1–(5–fluoropentyl)–1H–indole–3–carboxylate (5–fluoro–1
	440	+	PB–22); 2
458	441
459		-	(66) 3–fluoro–N–methylcathinone (3–FMC);
	442	+	(53) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(4–fluorobenzyl)–1H–3
	443	+	indazole–3–carboxamide (AB–FUBINACA); 4
460	444
461		-	(67) 1–(naphthalen–2–yl)–2–(pyrrolidin–1–yl)pentan–1–one (naphyrone);
	445	+	(54) N–(1–amino–3, 3 –dimethyl–1–oxobutan–2–yl)–1–pentyl–1H–5
	446	+	indazole–3–carboxamide (ADB–PINACA); 6
462	447
463		-	(68) alpha–pyrrolidinobutiophenone (alpha–PBP);
	448	+	(55) 2–(4–iodo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 7
	449	+	(25I–NBOMe); 8
464	450
465		-	(69) N–(~~1–amino–3–methyl–1–oxobutan–~~2–yl)~~–1–(cyclohexylmethyl)–1H–~~
466		-	~~indazole~~–~~3–carboxamide (AB–CHMINACA~~);
	451	+	(56) 2–(4–chloro–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 9
	452	+	(25C–NBOMe); 10
467	453
468		-	(70) N–(~~1–amino–3–methyl–1–oxobutan–~~2–yl)~~–1–pentyl–1H–indazole–3–~~
469		-	~~carboxamide~~ (AB–~~PINACA~~);
	454	+	(57) 2–(4–bromo–2,5–dimethoxyphenyl)–N–(2–methoxybenzyl) ethanamine 11
	455	+	(25B–NBOMe); 12
470	456
471		-	(71) [1–(5–fluoropentyl)–1H–indazol–3–yl](naphthalen–1–yl)methanone
472		-	(THJ–2201); and
	457	+	(58) marijuana extract (meaning an extract containing one or more 13
	458	+	cannabinoids that has been derived from any plant of the genus cannabis, other than the 14
	459	+	separated resin, whether crude or purified, obtained from the plant); 15
473	460
474		-	(72) N–(1–amino–3,3–dimethyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–
475		-	1H–indazole–3–carboxamide (MAB–CHMINACA).
	461	+	(59) 4–methyl–N–ethylcathinone (4–MEC); 16
476	462
477		-	(e) Unless specifically excepted under this subtitle or listed in another schedule,
478		-	a material, compound, mixture, or preparation that contains any quantity of the following
479		-	substances having depressant effects on the central nervous system, or that contains its LAWRENCE J. HOGAN, JR., Governor Ch. 285
	463	+	(60) 4–methyl–alpha–pyrrolidinopropiophenone (4–MePPP); 17
480	464
481		-	– 11 –
482		-	salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of
483		-	isomers is possible within the specific chemical designation, is a substance listed in
484		-	Schedule I:
	465	+	(61) alpha–pyrrolidinopentiophenone (alpha–PVP); 18
485	466
486		-	(1) ~~gamma~~–~~hydroxybutyric acid~~ (~~GHB~~);
	467	+	(62) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) butan–1–one (butylone); 19
487	468
488		-	(2) ~~mecloqualone~~; ~~and~~
	469	+	(63) 2–(methylamino)–1–phenylpentan–1–one (pentedrone); 20
489	470
490		-	(3) ~~methaqualone.~~
	471	+	(64) 1–(1,3–benzodioxol–5–yl)–2–(methylamino) pentan–1–one (pentylone); 21
491	472
492		-	(f) Unless specifically excepted or listed in another schedule, any material,
493		-	compound, mixture, or preparation that contains any quantity of the following substances
494		-	having a stimulant effect on the central nervous system, or that contains its salts, isomers,
495		-	or salts of isomers, is a substance listed in Schedule I:
	473	+	(65) 4–fluoro–N–methylcathinone (flephedrone); 22
496	474
497		-	(1) ~~aminorex~~;
	475	+	(66) 3–fluoro–N–methylcathinone (3–FMC); 23
498	476
499		-	(2) N–~~benzylpiperazine~~ (~~BZP~~);
	477	+	(67) 1–(naphthalen–2–yl)–2–(pyrrolidin–1–yl)pentan–1–one (naphyrone); 24
500	478
501		-	(3) ~~cathinone~~;
	479	+	(68) alpha–pyrrolidinobutiophenone (alpha–PBP); 25
502	480
503		-	(4) fenethylline;
	481	+	(69) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–1H–26
	482	+	indazole–3–carboxamide (AB–CHMINACA); 27
504	483
505		-	(5) methcathinone;
	484	+	(70) N–(1–amino–3–methyl–1–oxobutan–2–yl)–1–pentyl–1H–indazole–3–28
	485	+	carboxamide (AB–PINACA); 29 HOUSE BILL 33 11
506	486
507		-	(6) (±)cis–4–methylaminorex ((±)cis–4,5–dihydro–4–methyl–5–phenyl–2–
508		-	oxazolamine);
509	487
510		-	(7) N–ethylamphetamine; and
511	488
512		-	(8) N, N–dimethylamphetamine.
	489	+	(71) [1–(5–fluoropentyl)–1H–indazol–3–yl](naphthalen–1–yl)methanone 1
	490	+	(THJ–2201); and 2
513	491
514		-	(g) Unless specifically excepted under this subtitle or listed in another schedule,
515		-	any material, compound, mixture, or preparation that contains any quantity of the
516		-	following substances, or that contains their salts, isomers, or salts of isomers, whenever the
517		-	existence of such salts, isomers, or salts of isomers is possible within the specific chemical
518		-	designation, is a substance listed in Schedule I:
	492	+	(72) N–(1–amino–3,3–dimethyl–1–oxobutan–2–yl)–1–(cyclohexylmethyl)–3
	493	+	1H–indazole–3–carboxamide (MAB–CHMINACA). 4
519	494
520		-	(1) 5–(1, 1–dimethylheptyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol
521		-	(CP–47,497);
	495	+	(e) Unless specifically excepted under this subtitle or listed in another schedule, 5
	496	+	a material, compound, mixture, or preparation that contains any quantity of the following 6
	497	+	substances having depressant effects on the central nervous system, or that contains its 7
	498	+	salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of 8
	499	+	isomers is possible within the specific chemical designation, is a substance listed in 9
	500	+	Schedule I: 10
522	501
523		-	(2) 5–(1,1–dimethyloctyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol (CP–
524		-	47,497 C8 homolog);
	502	+	(1) gamma–hydroxybutyric acid (GHB); 11
525	503
526		-	(3) 1–pentyl–3–(1–naphthoyl) indole (JWH–018 and AM678);
527		-	Ch. 285 2022 LAWS OF MARYLAND
	504	+	(2) mecloqualone; and 12
528	505
529		-	– 12 –
530		-	(4) 1–butyl–3–(1–naphthoyl) indole (JWH–073);
	506	+	(3) methaqualone. 13
531	507
532		-	(5) 1–hexyl–3–(1–naphthoyl) indole (JWH–019);
	508	+	(f) Unless specifically excepted or listed in another schedule, any material, 14
	509	+	compound, mixture, or preparation that contains any quantity of the following substances 15
	510	+	having a stimulant effect on the central nervous system, or that contains its salts, isomers, 16
	511	+	or salts of isomers, is a substance listed in Schedule I: 17
533	512
534		-	(6) ~~1–[2–(4–morpholinyl)ethyl]–3–(1–naphthoyl) indole (JWH–200)~~;
	513	+	(1) aminorex; 18
535	514
536		-	(7) 1–~~pentyl–3–(2–methoxyphenylacetyl) indole~~ (~~JWH–250~~);
	515	+	(2) N–benzylpiperazine (BZP); 19
537	516
538		-	(8) ~~1–pentyl–3–[1–(4–methoxynaphthoyl)] indole (JWH–081)~~;
	517	+	(3) cathinone; 20
539	518
540		-	(9) ~~1–pentyl–3–(4–methyl–1–naphthoyl) indole (JWH–122)~~;
	519	+	(4) fenethylline; 21
541	520
542		-	(10) ~~1–pentyl–3–(4–chloro–1–naphthoyl) indole (JWH–398)~~;
	521	+	(5) methcathinone; 22
543	522
544		-	(11) 1–(5–fluoropentyl)–3–(1–naphthoyl) indole (AM2201);
	523	+	(6) (±)cis–4–methylaminorex ((±)cis–4,5–dihydro–4–methyl–5–phenyl–2–23
	524	+	oxazolamine); 24
545	525
546		-	(12) 1–~~(5–fluoropentyl)–3–(2–iodobenzoyl) indole (AM694)~~;
	526	+	(7) N–ethylamphetamine; and 25
547	527
548		-	(13) 1–~~pentyl–3–[(4–methoxy)–benzoyl] indole (SR–19 and RCS–4);~~
	528	+	(8) N, N–dimethylamphetamine. 26
549	529
550		-	(14) 1–cyclohexylethyl–3–(2–methoxyphenylacetyl) indole 7008 (SR–18 and
551		-	RCS–8); and
	530	+	(g) Unless specifically excepted under this subtitle or listed in another schedule, 27
	531	+	any material, compound, mixture, or preparation that contains any quantity of the 28
	532	+	following substances, or that contains their salts, isomers, or salts of isomers, whenever the 29
	533	+	existence of such salts, isomers, or salts of isomers is possible within the specific chemical 30
	534	+	designation, is a substance listed in Schedule I: 31 12 HOUSE BILL 33
552	535
553		-	(15) 1–pentyl–3–(2–chlorophenylacetyl) indole (JWH–203).
554	536
555		-	(h)] (B) (1) In this subsection:
556	537
557		-	(i) “controlled dangerous substance analogue” means a substance:
	538	+	(1) 5–(1, 1–dimethylheptyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol 1
	539	+	(CP–47,497); 2
558	540
559		-	1. that has a chemical structure substantially similar to the
560		-	chemical structure of a controlled dangerous substance [listed] DESCRIBED in Schedule I
561		-	or Schedule II; and
	541	+	(2) 5–(1,1–dimethyloctyl)–2–[(1R,3S)–3–hydroxycyclohexyl]–phenol (CP–3
	542	+	47,497 C8 homolog); 4
562	543
563		-	2. that has a stimulant, depressant, or hallucinogenic effect
564		-	on the central nervous system that is substantially similar to or greater than the stimulant,
565		-	depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous
566		-	substance [listed] DESCRIBED in Schedule I or Schedule II; but
	544	+	(3) 1–pentyl–3–(1–naphthoyl) indole (JWH–018 and AM678); 5
567	545
568		-	(ii) ~~“controlled dangerous substance analogue”~~ ~~does not include:~~
	546	+	(4) 1–butyl–3–(1–naphthoyl) indole (JWH–073); 6
569	547
570		-	1~~. a controlled dangerous substance~~;
	548	+	(5) 1–hexyl–3–(1–naphthoyl) indole (JWH–019); 7
571	549
572		-	2. a substance for which there is an approved new drug
573		-	application; or
574		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	550	+	(6) 1–[2–(4–morpholinyl)ethyl]–3–(1–naphthoyl) indole (JWH–200); 8
575	551
576		-	– 13 –
577		-	3. a substance exempted for investigational use under § 506
578		-	of the Federal Food, Drug, and Cosmetic Act.
	552	+	(7) 1–pentyl–3–(2–methoxyphenylacetyl) indole (JWH–250); 9
579	553
580		-	(2) To the extent intended for human consumption, each controlled
581		-	dangerous substance analogue is a substance [listed] DESCRIBED in Schedule I.
	554	+	(8) 1–pentyl–3–[1–(4–methoxynaphthoyl)] indole (JWH–081); 10
582	555
583		-	[(i)] (C) The Department may not add a substance to Schedule I under § 5–202
584		-	of this title unless the Department finds:
	556	+	(9) 1–pentyl–3–(4–methyl–1–naphthoyl) indole (JWH–122); 11
585	557
586		-	(1) ~~a high potential for abuse of the substance~~;
	558	+	(10) 1–pentyl–3–(4–chloro–1–naphthoyl) indole (JWH–398); 12
587	559
588		-	(2) ~~no accepted medical use in the United States for the substance~~; ~~and~~
	560	+	(11) 1–(5–fluoropentyl)–3–(1–naphthoyl) indole (AM2201); 13
589	561
590		-	(3) a lack of accepted safety for use of the substance under medical
591		-	supervision.
	562	+	(12) 1–(5–fluoropentyl)–3–(2–iodobenzoyl) indole (AM694); 14
592	563
593		-	5–~~403.~~
	564	+	(13) 1–pentyl–3–[(4–methoxy)–benzoyl] indole (SR–19 and RCS–4); 15
594	565
595		-	(a) Schedule II consists of each controlled dangerous substance:
	566	+	(14) 1–cyclohexylethyl–3–(2–methoxyphenylacetyl) indole 7008 (SR–18 and 16
	567	+	RCS–8); and 17
596	568
597		-	[(1) ~~listed in this section;~~
	569	+	(15) 1–pentyl–3–(2–chlorophenylacetyl) indole (JWH–203). 18
598	570
599		-	(2)] (1) added to Schedule II by the Department under § 5–202(b) of this
600		-	title; or
	571	+	(h)] (B) (1) In this subsection: 19
601	572
602		-	[(3)] (2) designated as a Schedule II controlled dangerous substance by
603		-	the federal government unless the Department objects under § 5–202(f) of this title.
	573	+	(i) “controlled dangerous substance analogue” means a substance: 20
604	574
605		-	[(b) Unless specifically excepted or unless listed in another schedule, any of the
606		-	following substances whether produced directly or indirectly by extraction from substances
607		-	of vegetable origin, or independently by means of chemical synthesis, or by a combination
608		-	of extraction and chemical synthesis:
	575	+	1. that has a chemical structure substantially similar to the 21
	576	+	chemical structure of a controlled dangerous substance [listed] DESCRIBED in Schedule I 22
	577	+	or Schedule II; and 23
609	578
610		-	(1) opium and opiate, and any salt, compound, derivative, or preparation
611		-	of opium or opiate excluding apomorphine, thebaine–derived butorphanol, dextrorphan,
612		-	nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, and naltrexone, and their
613		-	respective salts, but including the following:
	579	+	2. that has a stimulant, depressant, or hallucinogenic effect 24
	580	+	on the central nervous system that is substantially similar to or greater than the stimulant, 25
	581	+	depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous 26
	582	+	substance [listed] DESCRIBED in Schedule I or Schedule II; but 27
	583	+	HOUSE BILL 33 13
614	584
615		-	(i) codeine;
616	585
617		-	(ii) ~~dihydroetorphine;~~
	586	+	(ii) “controlled dangerous substance analogue” does not include: 1
618	587
619		-	~~(iii) ethylmorphine~~;
	588	+	1. a controlled dangerous substance; 2
620	589
621		-	~~(iv) etorphine hydrochloride;~~
622		-	~~Ch.~~ ~~285 2022 LAWS OF MARYLAND~~
	590	+	2. a substance for which there is an approved new drug 3
	591	+	application; or 4
623	592
624		-	~~– 14 –~~
625		-	~~(v) granulated opium;~~
	593	+	3. a substance exempted for investigational use under § 506 5
	594	+	of the Federal Food, Drug, and Cosmetic Act. 6
626	595
627		-	(vi) hydrocodone;
	596	+	(2) To the extent intended for human consumption, each controlled 7
	597	+	dangerous substance analogue is a substance [listed] DESCRIBED in Schedule I. 8
628	598
629		-	(vii) hydromorphone;
	599	+	[(i)] (C) The Department may not add a substance to Schedule I under § 5–202 9
	600	+	of this title unless the Department finds: 10
630	601
631		-	(~~viii~~) ~~metopon~~;
	602	+	(1) a high potential for abuse of the substance; 11
632	603
633		-	(ix) ~~morphine~~;
	604	+	(2) no accepted medical use in the United States for the substance; and 12
634	605
635		-	(x) opium extracts;
	606	+	(3) a lack of accepted safety for use of the substance under medical 13
	607	+	supervision. 14
636	608
637		-	~~(xi) opium fluid;~~
	609	+	5–403. 15
638	610
639		-	(~~xii~~) ~~oripavine;~~
	611	+	(a) Schedule II consists of each controlled dangerous substance: 16
640	612
641		-	(~~xiii~~) ~~oxycodone~~;
	613	+	[(1) listed in this section; 17
642	614
643		-	(xiv) oxymorphone;
	615	+	(2)] (1) added to Schedule II by the Department under § 5–202(b) of this 18
	616	+	title; or 19
644	617
645		-	(xv) powdered opium;
	618	+	[(3)] (2) designated as a Schedule II controlled dangerous substance by 20
	619	+	the federal government unless the Department objects under § 5–202(f) of this title. 21
646	620
647		-	(xvi) raw opium;
	621	+	[(b) Unless specifically excepted or unless listed in another schedule, any of the 22
	622	+	following substances whether produced directly or indirectly by extraction from substances 23
	623	+	of vegetable origin, or independently by means of chemical synthesis, or by a combination 24
	624	+	of extraction and chemical synthesis: 25
648	625
649		-	(xvii) thebaine; and
	626	+	(1) opium and opiate, and any salt, compound, derivative, or preparation 26
	627	+	of opium or opiate excluding apomorphine, thebaine–derived butorphanol, dextrorphan, 27
	628	+	nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, and naltrexone, and their 28
	629	+	respective salts, but including the following: 29
650	630
651		-	(~~xviii~~) ~~tincture of opium~~;
	631	+	(i) codeine; 30 14 HOUSE BILL 33
652	632
653		-	(2) any salt, compound, derivative, or preparation thereof which is
654		-	chemically equivalent or identical with any of the substances referred to in item (1) of this
655		-	subsection, except that these substances may not include the isoquinoline alkaloids of
656		-	opium;
657	633
658		-	(3) opium poppy and poppy straw;
659	634
660		-	(4) coca leaves and any salt, compound, derivative, or preparation of coca
661		-	leaves, including cocaine and ecgonine and their salts, isomers, derivatives and salts of
662		-	isomers and derivatives, and any salt, compound, derivative, or preparation thereof which
663		-	is chemically equivalent or identical with any of these substances, except that the
664		-	substances may not include:
	635	+	(ii) dihydroetorphine; 1
665	636
666		-	(i) decocainized coca leaves or extraction of coca leaves, which
667		-	extractions do not contain cocaine or ecgonine; or
	637	+	(iii) ethylmorphine; 2
668	638
669		-	(ii) ioflupane; and
670		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	639	+	(iv) etorphine hydrochloride; 3
671	640
672		-	– 15 –
673		-	(5) concentrate of poppy straw (the crude extract of poppy straw in either
674		-	liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium
675		-	poppy).
	641	+	(v) granulated opium; 4
676	642
677		-	(c) Unless specifically excepted or unless in another schedule any of the following
678		-	opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers
679		-	whenever the existence of such isomers, esters, ethers, and salts is possible within the
680		-	specific chemical designation, dextrorphan and levopropoxyphene excepted:
	643	+	(vi) hydrocodone; 5
681	644
682		-	(1) ~~alfentanil~~;
	645	+	(vii) hydromorphone; 6
683	646
684		-	(2) ~~alphaprodine~~;
	647	+	(viii) metopon; 7
685	648
686		-	(3) ~~anileridine~~;
	649	+	(ix) morphine; 8
687	650
688		-	(4) ~~bezitramide~~;
	651	+	(x) opium extracts; 9
689	652
690		-	(5) ~~bulk dextropropoxyphene (non–dosage forms)~~;
	653	+	(xi) opium fluid; 10
691	654
692		-	(6) ~~carfentanil~~;
	655	+	(xii) oripavine; 11
693	656
694		-	(7) ~~dihydrocodeine~~;
	657	+	(xiii) oxycodone; 12
695	658
696		-	(8) ~~diphenoxylate~~;
	659	+	(xiv) oxymorphone; 13
697	660
698		-	(9) ~~fentanyl~~;
	661	+	(xv) powdered opium; 14
699	662
700		-	(10) ~~isomethadone~~;
	663	+	(xvi) raw opium; 15
701	664
702		-	(11) ~~levo–alphacetylmethadol~~;
	665	+	(xvii) thebaine; and 16
703	666
704		-	(12) ~~levomethorphan~~;
	667	+	(xviii) tincture of opium; 17
705	668
706		-	(13) levorphanol;
	669	+	(2) any salt, compound, derivative, or preparation thereof which is 18
	670	+	chemically equivalent or identical with any of the substances referred to in item (1) of this 19
	671	+	subsection, except that these substances may not include the isoquinoline alkaloids of 20
	672	+	opium; 21
707	673
708		-	(14) ~~metazocine~~;
	674	+	(3) opium poppy and poppy straw; 22
709	675
710		-	(15) methadone;
	676	+	(4) coca leaves and any salt, compound, derivative, or preparation of coca 23
	677	+	leaves, including cocaine and ecgonine and their salts, isomers, derivatives and salts of 24
	678	+	isomers and derivatives, and any salt, compound, derivative, or preparation thereof which 25
	679	+	is chemically equivalent or identical with any of these substances, except that the 26
	680	+	substances may not include: 27 HOUSE BILL 33 15
711	681
712		-	(16) methadone – intermediate, 4–cyano–2–dimethylamino–4, 4–diphenyl
713		-	butane;
714	682
715		-	(17) moramide – intermediate, 2–methyl–3–morpholino–1, 1–
716		-	diphenylpropane–carboxylic acid;
717	683
718		-	(18) pethidine (meperidine); Ch. 285 2022 LAWS OF MARYLAND
	684	+	(i) decocainized coca leaves or extraction of coca leaves, which 1
	685	+	extractions do not contain cocaine or ecgonine; or 2
719	686
720		-	~~– 16 –~~
	687	+	(ii) ioflupane; and 3
721	688
722		-	(19) pethidine – intermediate – A, 4–cyano–1–methyl–4–phenylpiperidine;
	689	+	(5) concentrate of poppy straw (the crude extract of poppy straw in either 4
	690	+	liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium 5
	691	+	poppy). 6
723	692
724		-	(20) pethidine – intermediate – B, ethyl–4–phenylpiperidine–4–carboxylate;
	693	+	(c) Unless specifically excepted or unless in another schedule any of the following 7
	694	+	opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers 8
	695	+	whenever the existence of such isomers, esters, ethers, and salts is possible within the 9
	696	+	specific chemical designation, dextrorphan and levopropoxyphene excepted: 10
725	697
726		-	(21) pethidine – intermediate – C, 1–methyl–4–phenylpiperidine–4–
727		-	carboxylic acid;
	698	+	(1) alfentanil; 11
728	699
729		-	(22) ~~phenazocine~~;
	700	+	(2) alphaprodine; 12
730	701
731		-	(23) ~~piminodine~~;
	702	+	(3) anileridine; 13
732	703
733		-	(24) ~~racemethorphan~~;
	704	+	(4) bezitramide; 14
734	705
735		-	(25) ~~racemorphan~~;
	706	+	(5) bulk dextropropoxyphene (non–dosage forms); 15
736	707
737		-	(26) ~~remifentanil~~;
	708	+	(6) carfentanil; 16
738	709
739		-	(27) ~~sulfentanil~~;
	710	+	(7) dihydrocodeine; 17
740	711
741		-	(28) ~~tapentadol~~; ~~and~~
	712	+	(8) diphenoxylate; 18
742	713
743		-	(29) ~~thiafentanil.~~
	714	+	(9) fentanyl; 19
744	715
745		-	(d) Unless specifically excepted under this subtitle or listed in another schedule,
746		-	a substance is listed in Schedule II if the substance includes a material, compound, mixture,
747		-	or preparation that contains any quantity of the following substances having a potential
748		-	for abuse associated with a stimulant effect on the central nervous system:
	716	+	(10) isomethadone; 20
749	717
750		-	(1) ~~amphetamine, its salts, optical isomers, and salts of its optical isomers~~;
	718	+	(11) levo–alphacetylmethadol; 21
751	719
752		-	(2) ~~methamphetamine, its salts, isomers, and salts of isomers~~;
	720	+	(12) levomethorphan; 22
753	721
754		-	(3) ~~phenmetrazine and its salts~~;
	722	+	(13) levorphanol; 23
755	723
756		-	(4) ~~methylphenidate~~; ~~and~~
	724	+	(14) metazocine; 24
757	725
758		-	(5) ~~lisdexamfetamine, its salts, isomers, and salts of isomers.~~
	726	+	(15) methadone; 25
759	727
760		-	(e) Unless specifically excepted under this subtitle or listed in another schedule,
761		-	a substance is listed in Schedule II if the substance includes a material, compound, mixture,
762		-	or preparation that contains any quantity of the following substances having a depressant
763		-	effect on the central nervous system, including its salts, isomers, and salts of isomers
764		-	whenever the existence of such salts, isomers, and salts of isomers is possible within the
765		-	specific chemical designation:
766		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	728	+	(16) methadone – intermediate, 4–cyano–2–dimethylamino–4, 4–diphenyl 26
	729	+	butane; 27 16 HOUSE BILL 33
767	730
768		-	– 17 –
769		-	(1) amobarbital;
770	731
771		-	(2) glutethimide;
772	732
773		-	(3) pentobarbital;
	733	+	(17) moramide – intermediate, 2–methyl–3–morpholino–1, 1–1
	734	+	diphenylpropane–carboxylic acid; 2
774	735
775		-	(4) ~~phencyclidine~~; ~~and~~
	736	+	(18) pethidine (meperidine); 3
776	737
777		-	(5) ~~secobarbital.~~
	738	+	(19) pethidine – intermediate – A, 4–cyano–1–methyl–4–phenylpiperidine; 4
778	739
779		-	(f) ~~As listed in Schedule II under Title 21 of the Code of Federal Regulations:~~
	740	+	(20) pethidine – intermediate – B, ethyl–4–phenylpiperidine–4–carboxylate; 5
780	741
781		-	(1) nabilone; and
	742	+	(21) pethidine – intermediate – C, 1–methyl–4–phenylpiperidine–4–6
	743	+	carboxylic acid; 7
782	744
783		-	(2) dronabinol [(–)–delta–9–trans tetrahydrocannabinol] in an oral
784		-	solution in a drug product approved for marketing by the United States Food and Drug
785		-	Administration.
	745	+	(22) phenazocine; 8
786	746
787		-	(g) Unless specifically excepted or unless listed in another schedule, any material,
788		-	compound, mixture, or preparation which contains any quantity of the following
789		-	substances:
	747	+	(23) piminodine; 9
790	748
791		-	(1) ~~immediate precursor to amphetamine and methamphetamine:~~
	749	+	(24) racemethorphan; 10
792	750
793		-	(i) ~~phenylacetone~~; ~~and~~
	751	+	(25) racemorphan; 11
794	752
795		-	(ii) ~~reserved~~;
	753	+	(26) remifentanil; 12
796	754
797		-	(2) ~~immediate precursors to phencyclidine (PCP):~~
	755	+	(27) sulfentanil; 13
798	756
799		-	(i) ~~1–phenylcyclohexylamine~~; and
	757	+	(28) tapentadol; and 14
800	758
801		-	(ii) ~~1–piperidinocyclohexanecarbonitrile (PCC); and~~
	759	+	(29) thiafentanil. 15
802	760
803		-	(3) immediate precursor to fentanyl:
	761	+	(d) Unless specifically excepted under this subtitle or listed in another schedule, 16
	762	+	a substance is listed in Schedule II if the substance includes a material, compound, mixture, 17
	763	+	or preparation that contains any quantity of the following substances having a potential 18
	764	+	for abuse associated with a stimulant effect on the central nervous system: 19
804	765
805		-	(i) ~~4–anilino–N–phenethylpiperidine (ANPP);~~ and
	766	+	(1) amphetamine, its salts, optical isomers, and salts of its optical isomers; 20
806	767
807		-	(ii) ~~reserved.~~
	768	+	(2) methamphetamine, its salts, isomers, and salts of isomers; 21
808	769
809		-	(h)] (B) The Department may not add a substance to Schedule II under § 5–202
810		-	of this title unless the Department finds:
	770	+	(3) phenmetrazine and its salts; 22
811	771
812		-	(1) a high potential for abuse of the substance;
813		-	Ch. 285 2022 LAWS OF MARYLAND
	772	+	(4) methylphenidate; and 23
814	773
815		-	– 18 –
816		-	(2) currently accepted medical use of the substance in the United States,
817		-	or currently accepted medical use with severe restrictions; and
	774	+	(5) lisdexamfetamine, its salts, isomers, and salts of isomers. 24
818	775
819		-	(3) evidence that abuse of the substance may lead to severe psychological
820		-	or physical dependence.
	776	+	(e) Unless specifically excepted under this subtitle or listed in another schedule, 25
	777	+	a substance is listed in Schedule II if the substance includes a material, compound, mixture, 26
	778	+	or preparation that contains any quantity of the following substances having a depressant 27 HOUSE BILL 33 17
821	779
822		-	5–404.
823	780
824		-	(a) Schedule III consists of each controlled dangerous substance by whatever
825		-	official name, common or usual name, chemical name, or brand name [designated]:
	781	+	effect on the central nervous system, including its salts, isomers, and salts of isomers 1
	782	+	whenever the existence of such salts, isomers, and salts of isomers is possible within the 2
	783	+	specific chemical designation: 3
826	784
827		-	[(1) ~~listed in this section~~;
	785	+	(1) amobarbital; 4
828	786
829		-	(2)] (1) added to Schedule III by the Department under § 5–202(b) of this
830		-	title; or
	787	+	(2) glutethimide; 5
831	788
832		-	[(3)] (2) designated as a Schedule III controlled dangerous substance by
833		-	the federal government unless the Department objects under § 5–202(f) of this title.
	789	+	(3) pentobarbital; 6
834	790
835		-	[(b) (1) Unless specifically excepted or listed in another schedule, a substance
836		-	is listed in Schedule III if the substance includes a material, compound, mixture, or
837		-	preparation that contains any quantity of the following substances having a stimulant
838		-	effect on the central nervous system:
	791	+	(4) phencyclidine; and 7
839	792
840		-	(i) those compounds, mixtures, or preparations in dosage unit form
841		-	containing any stimulant substances listed in Schedule II, which compounds, mixtures, or
842		-	preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the
843		-	Code of Federal Regulations, and any other drug of the quantitative composition shown in
844		-	that list for those drugs or that is the same except that it contains a lesser quantity of
845		-	controlled substances;
	793	+	(5) secobarbital. 8
846	794
847		-	(ii) ~~benzphetamine;~~
	795	+	(f) As listed in Schedule II under Title 21 of the Code of Federal Regulations: 9
848	796
849		-	(~~iii~~) ~~chlorphentermine~~;
	797	+	(1) nabilone; and 10
850	798
851		-	(iv) clortermine; and
	799	+	(2) dronabinol [(–)–delta–9–trans tetrahydrocannabinol] in an oral 11
	800	+	solution in a drug product approved for marketing by the United States Food and Drug 12
	801	+	Administration. 13
852	802
853		-	(v) phendimetrazine.
	803	+	(g) Unless specifically excepted or unless listed in another schedule, any material, 14
	804	+	compound, mixture, or preparation which contains any quantity of the following 15
	805	+	substances: 16
854	806
855		-	(2) Subject to paragraph (3) of this subsection, substances in Schedule III
856		-	include:
	807	+	(1) immediate precursor to amphetamine and methamphetamine: 17
857	808
858		-	(i) ~~a salt of a substance listed in this subsection~~;
	809	+	(i) phenylacetone; and 18
859	810
860		-	(ii) an optical, position, or geometric isomer of a substance listed in
861		-	this subsection; or LAWRENCE J. HOGAN, JR., Governor Ch. 285
	811	+	(ii) reserved; 19
862	812
863		-	~~– 19 –~~
	813	+	(2) immediate precursors to phencyclidine (PCP): 20
864	814
865		-	(~~iii~~) ~~a salt of an isomer of a substance listed in this subsection.~~
	815	+	(i) 1–phenylcyclohexylamine; and 21
866	816
867		-	(3) Unless listed in another schedule, a salt, isomer, or salt of an isomer
868		-	described in paragraph (2) of this subsection may be included in Schedule III only if the
869		-	existence of the salts, isomers, and salts of isomers is possible within the specific chemical
870		-	designation.
	817	+	(ii) 1–piperidinocyclohexanecarbonitrile (PCC); and 22
871	818
872		-	(c) Unless listed in another schedule, a substance is listed in Schedule III if the
873		-	substance includes a material, compound, mixture, or preparation that contains any
874		-	quantity of the following substances having a potential for abuse associated with a
875		-	depressant effect on the central nervous system:
	819	+	(3) immediate precursor to fentanyl: 23
876	820
877		-	(1) ~~any compound,~~ ~~mixture, or preparation containing:~~
	821	+	(i) 4–anilino–N–phenethylpiperidine (ANPP); and 24
878	822
879		-	(i) ~~amobarbital;~~
	823	+	(ii) reserved. 25
880	824
881		-	(ii) secobarbital;
	825	+	(h)] (B) The Department may not add a substance to Schedule II under § 5–202 26
	826	+	of this title unless the Department finds: 27
	827	+	18 HOUSE BILL 33
882	828
883		-	(iii) pentobarbital; or
884	829
885		-	(iv) any salt thereof and one or more other active medicinal
886		-	ingredients that are not listed in any schedule;
	830	+	(1) a high potential for abuse of the substance; 1
887	831
888		-	(2) any suppository dosage form containing:
	832	+	(2) currently accepted medical use of the substance in the United States, 2
	833	+	or currently accepted medical use with severe restrictions; and 3
889	834
890		-	(i) amobarbital;
	835	+	(3) evidence that abuse of the substance may lead to severe psychological 4
	836	+	or physical dependence. 5
891	837
892		-	~~(ii) secobarbital;~~
	838	+	5–404. 6
893	839
894		-	(iii) pentobarbital; or
	840	+	(a) Schedule III consists of each controlled dangerous substance by whatever 7
	841	+	official name, common or usual name, chemical name, or brand name [designated]: 8
895	842
896		-	(iv) any salt of any of these drugs and approved by the U.S. Food and
897		-	Drug Administration for marketing only as a suppository;
	843	+	[(1) listed in this section; 9
898	844
899		-	(3) except those substances that are specifically listed in other schedules,
900		-	a substance that contains any quantity of a derivative of barbituric acid, a salt of a
901		-	derivative of a barbituric acid, or butalbital, including, with one or more active, nonnarcotic
902		-	ingredients in recognized therapeutic amounts, (Fioricet) and (Fiorinal);
	845	+	(2)] (1) added to Schedule III by the Department under § 5–202(b) of this 10
	846	+	title; or 11
903	847
904		-	(4) chlorhexadol;
	848	+	[(3)] (2) designated as a Schedule III controlled dangerous substance by 12
	849	+	the federal government unless the Department objects under § 5–202(f) of this title. 13
905	850
906		-	(5) embutramide;
907		-	Ch. 285 2022 LAWS OF MARYLAND
	851	+	[(b) (1) Unless specifically excepted or listed in another schedule, a substance 14
	852	+	is listed in Schedule III if the substance includes a material, compound, mixture, or 15
	853	+	preparation that contains any quantity of the following substances having a stimulant 16
	854	+	effect on the central nervous system: 17
908	855
909		-	– 20 –
910		-	(6) any drug product containing gamma hydroxybutyric acid, including its
911		-	salts, isomers, and salts of isomers, for which an application is approved under Section 505
912		-	of the Federal Food, Drug, and Cosmetic Act;
	856	+	(i) those compounds, mixtures, or preparations in dosage unit form 18
	857	+	containing any stimulant substances listed in Schedule II, which compounds, mixtures, or 19
	858	+	preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the 20
	859	+	Code of Federal Regulations, and any other drug of the quantitative composition shown in 21
	860	+	that list for those drugs or that is the same except that it contains a lesser quantity of 22
	861	+	controlled substances; 23
913	862
914		-	(7) ~~ketamine, its salts, isomers, and salts of isomers~~;
	863	+	(ii) benzphetamine; 24
915	864
916		-	(8) ~~lysergic acid~~;
	865	+	(iii) chlorphentermine; 25
917	866
918		-	(9) ~~lysergic acid amide~~;
	867	+	(iv) clortermine; and 26
919	868
920		-	(10) ~~methyprylon;~~
	869	+	(v) phendimetrazine. 27
921	870
922		-	(11) perampanel, and its salts, isomers, and salts of isomers (FYCOMPA);
	871	+	(2) Subject to paragraph (3) of this subsection, substances in Schedule III 28
	872	+	include: 29
923	873
924		-	(12) sulfondiethylmethane;
	874	+	(i) a salt of a substance listed in this subsection; 30
	875	+	HOUSE BILL 33 19
925	876
926		-	(13) sulfonethylmethane;
927	877
928		-	(14) sulfonmethane; and
	878	+	(ii) an optical, position, or geometric isomer of a substance listed in 1
	879	+	this subsection; or 2
929	880
930		-	(15) tiletamine and zolazepam or any salt thereof, including a tiletamine–
931		-	zolazepam combination product (trade name Telazol).
	881	+	(iii) a salt of an isomer of a substance listed in this subsection. 3
932	882
933		-	(d) As listed in Schedule III under Title 21 of the Code of Federal Regulations,
934		-	nalorphine 9400.
	883	+	(3) Unless listed in another schedule, a salt, isomer, or salt of an isomer 4
	884	+	described in paragraph (2) of this subsection may be included in Schedule III only if the 5
	885	+	existence of the salts, isomers, and salts of isomers is possible within the specific chemical 6
	886	+	designation. 7
935	887
936		-	(e) Unless specifically excepted or unless listed in another schedule:
	888	+	(c) Unless listed in another schedule, a substance is listed in Schedule III if the 8
	889	+	substance includes a material, compound, mixture, or preparation that contains any 9
	890	+	quantity of the following substances having a potential for abuse associated with a 10
	891	+	depressant effect on the central nervous system: 11
937	892
938		-	(1) substances listed in Schedule III include any material, compound,
939		-	mixture, or preparation containing any of the following narcotic drugs, or their salts
940		-	calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
	893	+	(1) any compound, mixture, or preparation containing: 12
941	894
942		-	(i) not more than 1.80 grams of codeine per 100 milliliters or not
943		-	more than 90 milligrams per dosage unit, with an equal or greater quantity of an
944		-	isoquinoline alkaloid of opium;
	895	+	(i) amobarbital; 13
945	896
946		-	(ii) not more than 1.80 grams of codeine per 100 milliliters or not
947		-	more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients
948		-	in recognized therapeutic amounts;
	897	+	(ii) secobarbital; 14
949	898
950		-	(iii) not more than 1.80 grams of dihydrocodeine per 100 milliliters
951		-	or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic
952		-	ingredients in recognized therapeutic amounts;
953		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	899	+	(iii) pentobarbital; or 15
954	900
955		-	– 21 –
956		-	(iv) not more than 300 milligrams of ethylmorphine per 100
957		-	milliliters or not more than 15 milligrams per dosage unit, with one or more active,
958		-	nonnarcotic ingredients in recognized therapeutic amounts;
	901	+	(iv) any salt thereof and one or more other active medicinal 16
	902	+	ingredients that are not listed in any schedule; 17
959	903
960		-	(v) not more than 500 milligrams of opium per 100 milliliters or per
961		-	100 grams, or not more than 25 milligrams per dosage unit, with one or more active,
962		-	nonnarcotic ingredients in recognized therapeutic amounts;
	904	+	(2) any suppository dosage form containing: 18
963	905
964		-	(vi) not more than 100 milligrams of opium per 100 milliliters or per
965		-	100 grams, or not more than 5 milligrams per dosage unit; and
	906	+	(i) amobarbital; 19
966	907
967		-	(vii) not more than 50 milligrams of morphine per 100 milliliters or
968		-	per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic
969		-	amounts.
	908	+	(ii) secobarbital; 20
970	909
971		-	(2) any material, compound, mixture, or preparation containing any of the
972		-	following narcotic drugs or their salts, as set forth below:
	910	+	(iii) pentobarbital; or 21
973	911
974		-	(i) buprenorphine; and
	912	+	(iv) any salt of any of these drugs and approved by the U.S. Food and 22
	913	+	Drug Administration for marketing only as a suppository; 23
975	914
976		-	(ii) reserved.
	915	+	(3) except those substances that are specifically listed in other schedules, 24
	916	+	a substance that contains any quantity of a derivative of barbituric acid, a salt of a 25
	917	+	derivative of a barbituric acid, or butalbital, including, with one or more active, nonnarcotic 26
	918	+	ingredients in recognized therapeutic amounts, (Fioricet) and (Fiorinal); 27
977	919
978		-	(3) if not combined with one or more active medicinal ingredients that are
979		-	listed in another schedule, substances listed in Schedule III include a suppository dosage
980		-	form or salt of a suppository dosage that contains:
	920	+	(4) chlorhexadol; 28
981	921
982		-	(i) amobarbital;
	922	+	(5) embutramide; 29
	923	+	20 HOUSE BILL 33
983	924
984		-	(ii) secobarbital; or
985	925
986		-	(iii) pentobarbital.
	926	+	(6) any drug product containing gamma hydroxybutyric acid, including its 1
	927	+	salts, isomers, and salts of isomers, for which an application is approved under Section 505 2
	928	+	of the Federal Food, Drug, and Cosmetic Act; 3
987	929
988		-	(f) (1) Except as provided in paragraph (2) of this subsection, an anabolic
989		-	steroid consisting of any material, compound, mixture, or preparation containing any
990		-	quantity of the following substances, including its salts, esters, and ethers:
	930	+	(7) ketamine, its salts, isomers, and salts of isomers; 4
991	931
992		-	(i) ~~3beta,17–dihydroxy–5a–androstane~~;
	932	+	(8) lysergic acid; 5
993	933
994		-	(ii) ~~3alpha,17beta–dihydroxy–5a–androstane~~;
	934	+	(9) lysergic acid amide; 6
995	935
996		-	(~~iii~~) ~~5 alpha–androstan–3,17–dione~~;
	936	+	(10) methyprylon; 7
997	937
998		-	(iv) 1–androstenediol (3beta,17beta–dihydroxy–5alpha–androst–1–
999		-	ene);
1000		-	Ch. 285 2022 LAWS OF MARYLAND
	938	+	(11) perampanel, and its salts, isomers, and salts of isomers (FYCOMPA); 8
1001	939
1002		-	– 22 –
1003		-	(v) 1–androstenediol (3alpha,17beta–dihydroxy–5alpha–androst–
1004		-	1–ene);
	940	+	(12) sulfondiethylmethane; 9
1005	941
1006		-	(vi) ~~4–androstenediol (3beta,17beta–dihydroxy–androst–4–ene)~~;
	942	+	(13) sulfonethylmethane; 10
1007	943
1008		-	(~~vii~~) ~~5–androstenediol (3beta,17beta–dihydroxy–androst–5–ene)~~;
	944	+	(14) sulfonmethane; and 11
1009	945
1010		-	(viii) 1–androstenedione;
	946	+	(15) tiletamine and zolazepam or any salt thereof, including a tiletamine–12
	947	+	zolazepam combination product (trade name Telazol). 13
1011	948
1012		-	(ix) 4–androstenedione;
	949	+	(d) As listed in Schedule III under Title 21 of the Code of Federal Regulations, 14
	950	+	nalorphine 9400. 15
1013	951
1014		-	(x) ~~5–androstenedione;~~
	952	+	(e) Unless specifically excepted or unless listed in another schedule: 16
1015	953
1016		-	(xi) bolasterone;
	954	+	(1) substances listed in Schedule III include any material, compound, 17
	955	+	mixture, or preparation containing any of the following narcotic drugs, or their salts 18
	956	+	calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: 19
1017	957
1018		-	(xii) boldenone;
	958	+	(i) not more than 1.80 grams of codeine per 100 milliliters or not 20
	959	+	more than 90 milligrams per dosage unit, with an equal or greater quantity of an 21
	960	+	isoquinoline alkaloid of opium; 22
1019	961
1020		-	(xiii) boldione;
	962	+	(ii) not more than 1.80 grams of codeine per 100 milliliters or not 23
	963	+	more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients 24
	964	+	in recognized therapeutic amounts; 25
1021	965
1022		-	(xiv) calusterone;
	966	+	(iii) not more than 1.80 grams of dihydrocodeine per 100 milliliters 26
	967	+	or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic 27
	968	+	ingredients in recognized therapeutic amounts; 28
1023	969
1024		-	(xv) chlorotestosterone (clostebol);
	970	+	(iv) not more than 300 milligrams of ethylmorphine per 100 29
	971	+	milliliters or not more than 15 milligrams per dosage unit, with one or more active, 30
	972	+	nonnarcotic ingredients in recognized therapeutic amounts; 31 HOUSE BILL 33 21
1025	973
1026		-	(xvi) dehydrochloromethyltestosterone;
1027	974
1028		-	(xvii) desoxymethyltestosterone;
1029	975
1030		-	(xviii) delta1–dihydrotestosterone (17beta–hydroxy–5alpha–androst–
1031		-	1–en–3–one);
	976	+	(v) not more than 500 milligrams of opium per 100 milliliters or per 1
	977	+	100 grams, or not more than 25 milligrams per dosage unit, with one or more active, 2
	978	+	nonnarcotic ingredients in recognized therapeutic amounts; 3
1032	979
1033		-	(~~xix~~) ~~dihydrotestosterone (~~4~~–dihydrotestosterone) (17beta–hydroxy–~~
1034		-	~~androstan–3–one) (stanolone)~~;
	980	+	(vi) not more than 100 milligrams of opium per 100 milliliters or per 4
	981	+	100 grams, or not more than 5 milligrams per dosage unit; and 5
1035	982
1036		-	(xx) drostanolone;
	983	+	(vii) not more than 50 milligrams of morphine per 100 milliliters or 6
	984	+	per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic 7
	985	+	amounts. 8
1037	986
1038		-	(xxi) ethylestrenol;
	987	+	(2) any material, compound, mixture, or preparation containing any of the 9
	988	+	following narcotic drugs or their salts, as set forth below: 10
1039	989
1040		-	(~~xxii~~) ~~fluoxymesterone~~;
	990	+	(i) buprenorphine; and 11
1041	991
1042		-	(~~xxiii~~) ~~formebolone;~~
	992	+	(ii) reserved. 12
1043	993
1044		-	(xxiv) furazabol;
	994	+	(3) if not combined with one or more active medicinal ingredients that are 13
	995	+	listed in another schedule, substances listed in Schedule III include a suppository dosage 14
	996	+	form or salt of a suppository dosage that contains: 15
1045	997
1046		-	(~~xxv~~) ~~13beta–ethyl–17beta–hydroxygon–4–en–3–one~~;
	998	+	(i) amobarbital; 16
1047	999
1048		-	(~~xxvi~~) ~~4–hydroxytestosterone~~; ~~LAWRENCE J. HOGAN, JR., Governor Ch. 285~~
	1000	+	(ii) secobarbital; or 17
1049	1001
1050		-	~~– 23 –~~
	1002	+	(iii) pentobarbital. 18
1051	1003
1052		-	(xxvii) 4–hydroxy–19–nortestosterone;
	1004	+	(f) (1) Except as provided in paragraph (2) of this subsection, an anabolic 19
	1005	+	steroid consisting of any material, compound, mixture, or preparation containing any 20
	1006	+	quantity of the following substances, including its salts, esters, and ethers: 21
1053	1007
1054		-	(xxviii) mestanolone (17alpha–methyl–17beta–hydroxy–5–
1055		-	androstan–3–one);
	1008	+	(i) 3beta,17–dihydroxy–5a–androstane; 22
1056	1009
1057		-	(~~xxix~~) ~~mesterolone~~;
	1010	+	(ii) 3alpha,17beta–dihydroxy–5a–androstane; 23
1058	1011
1059		-	(xxx) methandienone (methandrostenolone) (17alpha –methyl–
1060		-	17beta–hydroxyandrost–1,4–dien–3–one);
	1012	+	(iii) 5 alpha–androstan–3,17–dione; 24
1061	1013
1062		-	(xxxi) methandriol;
	1014	+	(iv) 1–androstenediol (3beta,17beta–dihydroxy–5alpha–androst–1–25
	1015	+	ene); 26
1063	1016
1064		-	(xxxii) methasterone;
	1017	+	(v) 1–androstenediol (3alpha,17beta–dihydroxy–5alpha–androst–27
	1018	+	1–ene); 28
1065	1019
1066		-	(xxxiii) methenolone;
	1020	+	(vi) 4–androstenediol (3beta,17beta–dihydroxy–androst–4–ene); 29
	1021	+	22 HOUSE BILL 33
1067	1022
1068		-	(xxxiv) 17alpha–methyl–3beta, 17beta –dihydroxy–5a–
1069		-	androstane;
1070	1023
1071		-	(~~xxxv~~) ~~17alpha~~–~~methyl–3alpha~~, 17beta–dihydroxy–5a–~~androstane~~;
	1024	+	(vii) 5–androstenediol (3beta,17beta–dihydroxy–androst–5–ene); 1
1072	1025
1073		-	(~~xxxvi~~) ~~17alpha~~–~~methyl–3beta, 17beta–dihydroxyandrost–4–ene~~;
	1026	+	(viii) 1–androstenedione; 2
1074	1027
1075		-	(~~xxxvii~~) ~~17alpha–methyl–~~4–~~hydroxynandrolone~~;
	1028	+	(ix) 4–androstenedione; 3
1076	1029
1077		-	(~~xxxviii~~) ~~methyldienolone~~;
	1030	+	(x) 5–androstenedione; 4
1078	1031
1079		-	(~~xxxix~~) ~~methyltrienolone~~;
	1032	+	(xi) bolasterone; 5
1080	1033
1081		-	(xl) ~~methyltestosterone~~;
	1034	+	(xii) boldenone; 6
1082	1035
1083		-	(~~xli~~) ~~mibolerone~~;
	1036	+	(xiii) boldione; 7
1084	1037
1085		-	(~~xlii~~) ~~17alpha–methyl–delta1–dihydrotestosterone~~;
	1038	+	(xiv) calusterone; 8
1086	1039
1087		-	(~~xliii~~) ~~nandrolone~~;
	1040	+	(xv) chlorotestosterone (clostebol); 9
1088	1041
1089		-	(~~xliv~~) ~~19–nor–4–androstenediol (3beta, 17beta–dihydroxyestr–4–ene)~~;
	1042	+	(xvi) dehydrochloromethyltestosterone; 10
1090	1043
1091		-	(xlv) 19–nor–4–androstenediol (3alpha, 17beta–dihydroxyestr–4–
1092		-	ene);
	1044	+	(xvii) desoxymethyltestosterone; 11
1093	1045
1094		-	(~~xlvi~~) 19–~~nor–5–androstenediol~~ (~~3beta,~~ 17beta–~~dihydroxyestr~~–5–~~ene);~~
1095		-	~~Ch. 285 2022 LAWS OF MARYLAND~~
	1046	+	(xviii) delta1–dihydrotestosterone (17beta–hydroxy–5alpha–androst–12
	1047	+	1–en–3–one); 13
1096	1048
1097		-	– 24 –
1098		-	(xlvii) 19–nor–5–androstenediol (3alpha, 17beta–dihydroxyestr–5–
1099		-	ene);
	1049	+	(xix) dihydrotestosterone (4–dihydrotestosterone) (17beta–hydroxy–14
	1050	+	androstan–3–one) (stanolone); 15
1100	1051
1101		-	(~~xlviii~~) ~~19–nor–4,9(10)–androstadienedione~~;
	1052	+	(xx) drostanolone; 16
1102	1053
1103		-	(~~xlix~~) ~~19–nor–4–androstenedione~~;
	1054	+	(xxi) ethylestrenol; 17
1104	1055
1105		-	(l) ~~19–nor–5–androstenedione~~;
	1056	+	(xxii) fluoxymesterone; 18
1106	1057
1107		-	(li) norbolethone (13beta, 17alpha–diethyl–17beta–hydroxygon–4–
1108		-	en–3–one);
	1058	+	(xxiii) formebolone; 19
1109	1059
1110		-	(~~lii~~) ~~norclostebol~~;
	1060	+	(xxiv) furazabol; 20
1111	1061
1112		-	(~~liii~~) ~~norethandrolone~~;
	1062	+	(xxv) 13beta–ethyl–17beta–hydroxygon–4–en–3–one; 21
1113	1063
1114		-	(~~liv~~) ~~normethandrolone~~;
	1064	+	(xxvi) 4–hydroxytestosterone; 22
1115	1065
1116		-	(lv) ~~oxandrolone~~;
	1066	+	(xxvii) 4–hydroxy–19–nortestosterone; 23
1117	1067
1118		-	(lvi) oxymesterone;
	1068	+	(xxviii) mestanolone (17alpha –methyl–17beta–hydroxy–5–24
	1069	+	androstan–3–one); 25
	1070	+	HOUSE BILL 33 23
1119	1071
1120		-	(lvii) oxymetholone;
1121	1072
1122		-	(~~lviii~~) ~~prostanozol~~;
	1073	+	(xxix) mesterolone; 1
1123	1074
1124		-	(lix) stanozolol;
	1075	+	(xxx) methandienone (methandrostenolone) (17alpha –methyl–2
	1076	+	17beta–hydroxyandrost–1,4–dien–3–one); 3
1125	1077
1126		-	(lx) ~~stenbolone~~;
	1078	+	(xxxi) methandriol; 4
1127	1079
1128		-	(~~lxi~~) ~~testolactone~~;
	1080	+	(xxxii) methasterone; 5
1129	1081
1130		-	(~~lxii~~) ~~testosterone~~;
	1082	+	(xxxiii) methenolone; 6
1131	1083
1132		-	(lxiii) tetrahydrogestrinone; and
	1084	+	(xxxiv) 17alpha–methyl–3beta, 17beta –dihydroxy–5a–7
	1085	+	androstane; 8
1133	1086
1134		-	(~~lxiv~~) ~~trenbolone.~~
	1087	+	(xxxv) 17alpha–methyl–3alpha, 17beta–dihydroxy–5a–androstane; 9
1135	1088
1136		-	(2) ~~The following substances are not included in Schedule III:~~
	1089	+	(xxxvi) 17alpha–methyl–3beta, 17beta–dihydroxyandrost–4–ene; 10
1137	1090
1138		-	(i) ~~an estrogen, progestin, or corticosteroid~~; or
	1091	+	(xxxvii) 17alpha–methyl–4–hydroxynandrolone; 11
1139	1092
1140		-	(ii) ~~a substance covered by paragraph (1) of this subsection if:~~
	1093	+	(xxxviii) methyldienolone; 12
1141	1094
1142		-	1. expressly intended for administration through implants to
1143		-	cattle or other nonhuman species; and LAWRENCE J. HOGAN, JR., Governor Ch. 285
	1095	+	(xxxix) methyltrienolone; 13
1144	1096
1145		-	~~– 25 –~~
	1097	+	(xl) methyltestosterone; 14
1146	1098
1147		-	2. approved for that use by the U.S. Food and Drug
1148		-	Administration.
	1099	+	(xli) mibolerone; 15
1149	1100
1150		-	(g) ~~Hallucinogenic substances include:~~
	1101	+	(xlii) 17alpha–methyl–delta1–dihydrotestosterone; 16
1151	1102
1152		-	(1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin
1153		-	capsule in a U.S. Food and Drug Administration–approved product; and
	1103	+	(xliii) nandrolone; 17
1154	1104
1155		-	(2) ~~reserved.~~
	1105	+	(xliv) 19–nor–4–androstenediol (3beta, 17beta–dihydroxyestr–4–ene); 18
1156	1106
1157		-	(h)] (~~B) The Department may not add a substance to Schedule III under §~~
1158		-	~~5–202 of this title unless the Department finds:~~
	1107	+	(xlv) 19–nor–4–androstenediol (3alpha, 17beta–dihydroxyestr–4–19
	1108	+	ene); 20
1159	1109
1160		-	(1) a potential for abuse of the substance that is less than that for the
1161		-	substances listed in Schedule I and Schedule II;
	1110	+	(xlvi) 19–nor–5–androstenediol (3beta, 17beta–dihydroxyestr–5–ene); 21
1162	1111
1163		-	(2) ~~well documented and approved medical use of the substance in the~~
1164		-	~~United States~~; ~~and~~
	1112	+	(xlvii) 19–nor–5–androstenediol (3alpha, 17beta–dihydroxyestr–5–22
	1113	+	ene); 23
1165	1114
1166		-	(3) evidence that abuse of the substance may lead to moderate or low
1167		-	physical dependence or high psychological dependence.
	1115	+	(xlviii) 19–nor–4,9(10)–androstadienedione; 24
1168	1116
1169		-	5–~~405.~~
	1117	+	(xlix) 19–nor–4–androstenedione; 25
1170	1118
1171		-	(a) ~~Schedule IV consists of each controlled dangerous substance:~~
	1119	+	(l) 19–nor–5–androstenedione; 26 24 HOUSE BILL 33
1172	1120
1173		-	[(1) listed in this section;
1174	1121
1175		-	(2)] (1) added to Schedule IV by the Department under § 5–202(b) of this
1176		-	title; or
1177	1122
1178		-	~~[(3)]~~ (2) ~~designated as a Schedule IV controlled dangerous substance by~~
1179		-	~~the federal government unless the Department objects under § 5–202(f) of this title.~~
	1123	+	(li) norbolethone (13beta, 17alpha–diethyl–17beta–hydroxygon–4–1
	1124	+	en–3–one); 2
1180	1125
1181		-	[(b) Unless specifically excepted or unless listed in another schedule, any material,
1182		-	compound, mixture, or preparation containing any of the following narcotic drugs, or their
1183		-	salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth
1184		-	below:
	1126	+	(lii) norclostebol; 3
1185	1127
1186		-	(1) not more than 1 milligram of difenoxin and not less than 25 micrograms
1187		-	of atropine sulfate per dosage unit;
	1128	+	(liii) norethandrolone; 4
1188	1129
1189		-	(2) dextropropoxyphene (alpha–(+)–4–dimethylamino–1, 2–diphenyl–3–
1190		-	methyl–2–propionoxybutane); and
1191		-	Ch. 285 2022 LAWS OF MARYLAND
	1130	+	(liv) normethandrolone; 5
1192	1131
1193		-	– 26 –
1194		-	(3) 2–[(dimethylamino)methyl]–1–(3–methoxyphenyl)cyclohexanol, its
1195		-	salts, optical and geometric isomers and salts of these isomers (including tramadol).
	1132	+	(lv) oxandrolone; 6
1196	1133
1197		-	(c) Substances listed in Schedule IV include a material, compound, mixture, or
1198		-	preparation that contains any quantity of the following substances having a potential for
1199		-	abuse associated with a depressant effect on the central nervous system, including its salts,
1200		-	isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of
1201		-	isomers is possible within the specific chemical designations:
	1134	+	(lvi) oxymesterone; 7
1202	1135
1203		-	(1) ~~alfaxalone~~;
	1136	+	(lvii) oxymetholone; 8
1204	1137
1205		-	(2) ~~alprazolam~~;
	1138	+	(lviii) prostanozol; 9
1206	1139
1207		-	(3) ~~barbital~~;
	1140	+	(lix) stanozolol; 10
1208	1141
1209		-	(4) ~~brexanolone~~;
	1142	+	(lx) stenbolone; 11
1210	1143
1211		-	(5) ~~bromazepam~~;
	1144	+	(lxi) testolactone; 12
1212	1145
1213		-	(6) ~~camazepam~~;
	1146	+	(lxii) testosterone; 13
1214	1147
1215		-	(7) ~~carisoprodol~~;
	1148	+	(lxiii) tetrahydrogestrinone; and 14
1216	1149
1217		-	(8) ~~chloral betaine;~~
	1150	+	(lxiv) trenbolone. 15
1218	1151
1219		-	(9) ~~chloral hydrate;~~
	1152	+	(2) The following substances are not included in Schedule III: 16
1220	1153
1221		-	(10) ~~chlordiazepoxide~~;
	1154	+	(i) an estrogen, progestin, or corticosteroid; or 17
1222	1155
1223		-	(11) ~~clobazam;~~
	1156	+	(ii) a substance covered by paragraph (1) of this subsection if: 18
1224	1157
1225		-	(12) clonazepam;
	1158	+	1. expressly intended for administration through implants to 19
	1159	+	cattle or other nonhuman species; and 20
1226	1160
1227		-	(13) clorazepate;
	1161	+	2. approved for that use by the U.S. Food and Drug 21
	1162	+	Administration. 22
1228	1163
1229		-	(14) ~~clotiazepam;~~
	1164	+	(g) Hallucinogenic substances include: 23
1230	1165
1231		-	(15) cloxazolam;
	1166	+	(1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin 24
	1167	+	capsule in a U.S. Food and Drug Administration–approved product; and 25
	1168	+	HOUSE BILL 33 25
1232	1169
1233		-	(16) delorazepam;
1234	1170
1235		-	(17) ~~diazepam;~~
	1171	+	(2) reserved. 1
1236	1172
1237		-	(18) dichloralphenazone;
	1173	+	(h)] (B) The Department may not add a substance to Schedule III under § 2
	1174	+	5–202 of this title unless the Department finds: 3
1238	1175
1239		-	(19) estazolam; LAWRENCE J. HOGAN, JR., Governor Ch. 285
	1176	+	(1) a potential for abuse of the substance that is less than that for the 4
	1177	+	substances listed in Schedule I and Schedule II; 5
1240	1178
1241		-	– 27 –
	1179	+	(2) well documented and approved medical use of the substance in the 6
	1180	+	United States; and 7
1242	1181
1243		-	(20) ethchlorvynol;
	1182	+	(3) evidence that abuse of the substance may lead to moderate or low 8
	1183	+	physical dependence or high psychological dependence. 9
1244	1184
1245		-	~~(21) ethinamate;~~
	1185	+	5–405. 10
1246	1186
1247		-	(22) ~~ethyl loflazepate;~~
	1187	+	(a) Schedule IV consists of each controlled dangerous substance: 11
1248	1188
1249		-	(23) ~~fludiazepam~~;
	1189	+	[(1) listed in this section; 12
1250	1190
1251		-	(24) flunitrazepam;
	1191	+	(2)] (1) added to Schedule IV by the Department under § 5–202(b) of this 13
	1192	+	title; or 14
1252	1193
1253		-	(25) flurazepam;
	1194	+	[(3)] (2) designated as a Schedule IV controlled dangerous substance by 15
	1195	+	the federal government unless the Department objects under § 5–202(f) of this title. 16
1254	1196
1255		-	(26) fospropofol;
	1197	+	[(b) Unless specifically excepted or unless listed in another schedule, any material, 17
	1198	+	compound, mixture, or preparation containing any of the following narcotic drugs, or their 18
	1199	+	salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth 19
	1200	+	below: 20
1256	1201
1257		-	(27) halazepam;
	1202	+	(1) not more than 1 milligram of difenoxin and not less than 25 micrograms 21
	1203	+	of atropine sulfate per dosage unit; 22
1258	1204
1259		-	(28) haloxazolam;
	1205	+	(2) dextropropoxyphene (alpha–(+)–4–dimethylamino–1, 2–diphenyl–3–23
	1206	+	methyl–2–propionoxybutane); and 24
1260	1207
1261		-	(29) ketazolam;
	1208	+	(3) 2–[(dimethylamino)methyl]–1–(3–methoxyphenyl)cyclohexanol, its 25
	1209	+	salts, optical and geometric isomers and salts of these isomers (including tramadol). 26
1262	1210
1263		-	(30) loprazolam;
	1211	+	(c) Substances listed in Schedule IV include a material, compound, mixture, or 27
	1212	+	preparation that contains any quantity of the following substances having a potential for 28
	1213	+	abuse associated with a depressant effect on the central nervous system, including its salts, 29
	1214	+	isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of 30
	1215	+	isomers is possible within the specific chemical designations: 31
1264	1216
1265		-	(31) ~~lorazepam~~;
	1217	+	(1) alfaxalone; 32 26 HOUSE BILL 33
1266	1218
1267		-	(32) lormetazepam;
1268	1219
1269		-	(33) mebutamate;
1270	1220
1271		-	(34) ~~medazepam~~;
	1221	+	(2) alprazolam; 1
1272	1222
1273		-	(35) ~~meprobamate~~;
	1223	+	(3) barbital; 2
1274	1224
1275		-	(36) ~~methohexital~~;
	1225	+	(4) brexanolone; 3
1276	1226
1277		-	(37) ~~methylphenobarbital (mephobarbital)~~;
	1227	+	(5) bromazepam; 4
1278	1228
1279		-	(38) ~~midazolam~~;
	1229	+	(6) camazepam; 5
1280	1230
1281		-	(39) ~~nimetazepam~~;
	1231	+	(7) carisoprodol; 6
1282	1232
1283		-	(40) ~~nitrazepam~~;
	1233	+	(8) chloral betaine; 7
1284	1234
1285		-	(41) ~~nordiazepam~~;
	1235	+	(9) chloral hydrate; 8
1286	1236
1287		-	(42) ~~oxazepam~~; ~~Ch. 285 2022 LAWS OF MARYLAND~~
	1237	+	(10) chlordiazepoxide; 9
1288	1238
1289		-	~~– 28 –~~
	1239	+	(11) clobazam; 10
1290	1240
1291		-	(43) ~~oxazolam~~;
	1241	+	(12) clonazepam; 11
1292	1242
1293		-	(44) ~~paraldehyde~~;
	1243	+	(13) clorazepate; 12
1294	1244
1295		-	(45) ~~petrichloral~~;
	1245	+	(14) clotiazepam; 13
1296	1246
1297		-	(46) ~~phenobarbital~~;
	1247	+	(15) cloxazolam; 14
1298	1248
1299		-	(47) ~~pinazepam~~;
	1249	+	(16) delorazepam; 15
1300	1250
1301		-	(48) ~~prazepam~~;
	1251	+	(17) diazepam; 16
1302	1252
1303		-	(49) ~~quazepam~~;
	1253	+	(18) dichloralphenazone; 17
1304	1254
1305		-	(50) ~~suvorexant (Belsomra)~~;
	1255	+	(19) estazolam; 18
1306	1256
1307		-	(51) ~~temazepam~~;
	1257	+	(20) ethchlorvynol; 19
1308	1258
1309		-	(52) ~~tetrazepam~~;
	1259	+	(21) ethinamate; 20
1310	1260
1311		-	(53) ~~triazolam~~;
	1261	+	(22) ethyl loflazepate; 21
1312	1262
1313		-	(54) ~~zaleplon (Sonata)~~;
	1263	+	(23) fludiazepam; 22
1314	1264
1315		-	(55) zolpidem (Ambien); and
	1265	+	(24) flunitrazepam; 23
	1266	+	HOUSE BILL 33 27
1316	1267
1317		-	(56) zopiclone (Lunesta).
1318	1268
1319		-	(d) ~~Substances listed in Schedule IV include:~~
	1269	+	(25) flurazepam; 1
1320	1270
1321		-	(1) a material, compound, mixture, or preparation that contains
1322		-	fenfluramine; and
	1271	+	(26) fospropofol; 2
1323	1272
1324		-	(2) ~~if its existence is possible:~~
	1273	+	(27) halazepam; 3
1325	1274
1326		-	(i) ~~a salt of fenfluramine~~;
	1275	+	(28) haloxazolam; 4
1327	1276
1328		-	(ii) an optical, position, or geometric isomer of fenfluramine,
1329		-	including dexfenfluramine; and
	1277	+	(29) ketazolam; 5
1330	1278
1331		-	(~~iii~~) ~~a salt of an isomer of fenfluramine.~~
	1279	+	(30) loprazolam; 6
1332	1280
1333		-	(e) Substances listed in Schedule IV include:
1334		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	1281	+	(31) lorazepam; 7
1335	1282
1336		-	– 29 –
1337		-	(1) a material, compound, mixture, or preparation that contains lorcaserin;
1338		-	and
	1283	+	(32) lormetazepam; 8
1339	1284
1340		-	(2) ~~if its existence is possible:~~
	1285	+	(33) mebutamate; 9
1341	1286
1342		-	(i) ~~a salt of lorcaserin~~;
	1287	+	(34) medazepam; 10
1343	1288
1344		-	(ii) ~~an optical, position, or geometric isomer of lorcaserin~~; ~~and~~
	1289	+	(35) meprobamate; 11
1345	1290
1346		-	(~~iii~~) ~~a salt of an isomer of lorcaserin.~~
	1291	+	(36) methohexital; 12
1347	1292
1348		-	(f) Substances listed in Schedule IV include a material, compound, mixture, or
1349		-	preparation that contains any quantity of the following substances having a potential for
1350		-	abuse associated with a stimulant effect on the central nervous system, including its salts,
1351		-	isomers, and salts of isomers:
	1293	+	(37) methylphenobarbital (mephobarbital); 13
1352	1294
1353		-	(1) ~~cathine ((+)–norpseudoephedrine)~~;
	1295	+	(38) midazolam; 14
1354	1296
1355		-	(2) ~~diethylpropion~~;
	1297	+	(39) nimetazepam; 15
1356	1298
1357		-	(3) ~~fencamfamin~~;
	1299	+	(40) nitrazepam; 16
1358	1300
1359		-	(4) ~~fenproporex~~;
	1301	+	(41) nordiazepam; 17
1360	1302
1361		-	(5) ~~mazindol~~;
	1303	+	(42) oxazepam; 18
1362	1304
1363		-	(6) ~~mefenorex~~;
	1305	+	(43) oxazolam; 19
1364	1306
1365		-	(7) ~~modafinil~~;
	1307	+	(44) paraldehyde; 20
1366	1308
1367		-	(8) ~~pemoline, including organometallic complexes and their chelates~~;
	1309	+	(45) petrichloral; 21
1368	1310
1369		-	(9) ~~phentermine~~;
	1311	+	(46) phenobarbital; 22
1370	1312
1371		-	(10) ~~pipradrol~~;
	1313	+	(47) pinazepam; 23
1372	1314
1373		-	(11) ~~sibutramine~~;
	1315	+	(48) prazepam; 24 28 HOUSE BILL 33
1374	1316
1375		-	(12) solriamfetol (2–amino–3–phenylpropyl carbamate; benzenepropanol,
1376		-	beta–amino–, carbamate (ester)); and
1377	1317
1378		-	(13) SPA ((–)–1–dimethylamino– 1,2–diphenylethane).
1379	1318
1380		-	(g) Unless specifically excepted or unless listed in another schedule, any material,
1381		-	compound, mixture, or preparation that contains any quantity of the following substances,
1382		-	including its salts: Ch. 285 2022 LAWS OF MARYLAND
	1319	+	(49) quazepam; 1
1383	1320
1384		-	~~– 30 –~~
	1321	+	(50) suvorexant (Belsomra); 2
1385	1322
1386		-	(1) ~~pentazocine~~;
	1323	+	(51) temazepam; 3
1387	1324
1388		-	(2) ~~butorphanol (including its optical isomers)~~; ~~and~~
	1325	+	(52) tetrazepam; 4
1389	1326
1390		-	(3) eluxadoline (5 –[[[(2S)–2–amino–3–[4–aminocarbonyl)–2, 6 –
1391		-	dimethylphenyl]–1–oxopropyl][(1S)–1–(4–phenyl–1H–imidazol–2–
1392		-	yl)ethyl]amino]methyl]–2–methoxybenzoic acid) (including its optical isomers) and its
1393		-	salts, isomers, and salts of isomers.
	1327	+	(53) triazolam; 5
1394	1328
1395		-	(h) By regulation, the Department may exempt from this section a compound,
1396		-	mixture, or preparation that contains a depressant substance listed in subsection (c) of this
1397		-	section if:
	1329	+	(54) zaleplon (Sonata); 6
1398	1330
1399		-	(1) the compound, mixture, or preparation contains an active medicinal
1400		-	ingredient that does not have a depressant effect on the central nervous system; and
	1331	+	(55) zolpidem (Ambien); and 7
1401	1332
1402		-	(2) the admixtures are included in combinations, quantity, proportion, or
1403		-	concentration that vitiate the potential for abuse of the substances that have a depressant
1404		-	effect on the central nervous system.
	1333	+	(56) zopiclone (Lunesta). 8
1405	1334
1406		-	(i)] (B) The Department may not add a substance to Schedule IV under §
1407		-	5–202 of this title unless the Department finds that:
	1335	+	(d) Substances listed in Schedule IV include: 9
1408	1336
1409		-	(1) ~~the substance has~~ a ~~low potential for abuse relative to the substances~~
1410		-	~~listed in Schedule III~~;
	1337	+	(1) a material, compound, mixture, or preparation that contains 10
	1338	+	fenfluramine; and 11
1411	1339
1412		-	(2) the substance has currently accepted medical use in treatment in the
1413		-	United States; and
	1340	+	(2) if its existence is possible: 12
1414	1341
1415		-	(3) abuse of the substance may lead to limited physical dependence or
1416		-	psychological dependence relative to the substances in Schedule III.
	1342	+	(i) a salt of fenfluramine; 13
1417	1343
1418		-	5–406.
	1344	+	(ii) an optical, position, or geometric isomer of fenfluramine, 14
	1345	+	including dexfenfluramine; and 15
1419	1346
1420		-	(a) ~~Schedule V consists~~ of ~~each controlled dangerous substance:~~
	1347	+	(iii) a salt of an isomer of fenfluramine. 16
1421	1348
1422		-	[(1) listed in ~~this section;~~
	1349	+	(e) Substances listed in Schedule IV include: 17
1423	1350
1424		-	~~(2)]~~ (1) ~~added to Schedule V by the Department under § 5–202(b) of this~~
1425		-	~~title; or~~
	1351	+	(1) a material, compound, mixture, or preparation that contains lorcaserin; 18
	1352	+	and 19
1426	1353
1427		-	[(3)] (2) designated as a Schedule V controlled dangerous substance by
1428		-	the federal government unless the Department objects under § 5–202(f) of this title.
1429		-	LAWRENCE J. HOGAN, JR., Governor Ch. 285
	1354	+	(2) if its existence is possible: 20
1430	1355
1431		-	– 31 –
1432		-	[(b) Unless specifically excepted or unless listed in another schedule, any material,
1433		-	compound, mixture, or preparation containing any of the following narcotic drugs and their
1434		-	salts, as set forth below:
	1356	+	(i) a salt of lorcaserin; 21
1435	1357
1436		-	(1) ~~reserved~~; and
	1358	+	(ii) an optical, position, or geometric isomer of lorcaserin; and 22
1437	1359
1438		-	(2) ~~reserved~~.
	1360	+	(iii) a salt of an isomer of lorcaserin. 23
1439	1361
1440		-	(c) Any compound, mixture, or preparation containing any of the following
1441		-	narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited
1442		-	quantities as set forth below, which shall include one or more nonnarcotic active medicinal
1443		-	ingredients in sufficient proportion to confer upon the compound, mixture, or preparation
1444		-	valuable medicinal qualities other than those possessed by narcotic drugs alone:
	1362	+	(f) Substances listed in Schedule IV include a material, compound, mixture, or 24
	1363	+	preparation that contains any quantity of the following substances having a potential for 25 HOUSE BILL 33 29
1445	1364
1446		-	(1) not more than 200 milligrams of codeine per 100 milliliters or per 100
1447		-	grams;
1448	1365
1449		-	~~(2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or~~
1450		-	~~per 100 grams;~~
	1366	+	abuse associated with a stimulant effect on the central nervous system, including its salts, 1
	1367	+	isomers, and salts of isomers: 2
1451	1368
1452		-	(3) not more than 100 milligrams of ethylmorphine per 100 milliliters or
1453		-	per 100 grams;
	1369	+	(1) cathine ((+)–norpseudoephedrine); 3
1454	1370
1455		-	(4) not more than 2.5 milligrams of diphenoxylate and not less than 25
1456		-	micrograms of atropine sulfate per dosage unit; or
	1371	+	(2) diethylpropion; 4
1457	1372
1458		-	(5) ~~difenoxin preparations 0.5mg/25ug ATSO4/DU (MOTOFEN).~~
	1373	+	(3) fencamfamin; 5
1459	1374
1460		-	(d) Unless specifically exempted or excluded or unless listed in another schedule,
1461		-	any material, compound, mixture, or preparation that contains any quantity of the
1462		-	following substances having a stimulant effect on the central nervous system, including its
1463		-	salts, isomers, and salts of isomers:
	1375	+	(4) fenproporex; 6
1464	1376
1465		-	(1) ~~pyrovalerone~~; ~~and~~
	1377	+	(5) mazindol; 7
1466	1378
1467		-	(2) ~~reserved.~~
	1379	+	(6) mefenorex; 8
1468	1380
1469		-	(e) Unless specifically exempted or excluded or unless listed in another schedule,
1470		-	any material, compound, mixture, or preparation that contains any quantity of the
1471		-	following substances having a depressant effect on the central nervous system, including
1472		-	its salts:
	1381	+	(7) modafinil; 9
1473	1382
1474		-	(1) brivaracetam ((2S) –2–[(4R)–2–oxo–4–propylpyrrolidin–1–yl]
1475		-	butanamide) (Briviact);
1476		-	Ch. 285 2022 LAWS OF MARYLAND
	1383	+	(8) pemoline, including organometallic complexes and their chelates; 10
1477	1384
1478		-	– 32 –
1479		-	(2) ezogabine [N–[2–amino–4–(4–fluorobenzylamino)–phenyl]–carbamic
1480		-	acid ethyl ester] (Potiga);
	1385	+	(9) phentermine; 11
1481	1386
1482		-	(3) lacosamide [(R)–2–acetoamido–N–benzyl–3–methoxy–propionamide]
1483		-	(Vimpat); and
	1387	+	(10) pipradrol; 12
1484	1388
1485		-	(4) ~~pregabalin [(S)–3–(aminomethyl)–5–methylhexanoic acid] (Lyrica).~~
	1389	+	(11) sibutramine; 13
1486	1390
1487		-	(f) A drug product in finished dosage formulation that has been approved by the
1488		-	United States Food and Drug Administration that contains cannabidiol (2–[1R–3–methyl–
1489		-	6R–(1–methylethenyl)–2–cyclohexen–1–yl]–5–pentyl–1,3–benzenediol) derived from
1490		-	cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols.
	1391	+	(12) solriamfetol (2–amino–3–phenylpropyl carbamate; benzenepropanol, 14
	1392	+	beta–amino–, carbamate (ester)); and 15
1491	1393
1492		-	(g)] (B) The Department may not add a substance to Schedule V under § 5–202
1493		-	of this title unless the Department finds:
	1394	+	(13) SPA ((–)–1–dimethylamino– 1,2–diphenylethane). 16
1494	1395
1495		-	(1) the substance has a low potential for abuse relative to the substances
1496		-	listed in Schedule IV;
	1396	+	(g) Unless specifically excepted or unless listed in another schedule, any material, 17
	1397	+	compound, mixture, or preparation that contains any quantity of the following substances, 18
	1398	+	including its salts: 19
1497	1399
1498		-	(2) the substance has currently accepted medical use in the United States;
1499		-	and
	1400	+	(1) pentazocine; 20
1500	1401
1501		-	(3) abuse of the substance may lead to limited physical dependence or
1502		-	psychological dependence liability relative to the substances listed in Schedule IV.
	1402	+	(2) butorphanol (including its optical isomers); and 21
1503	1403
1504		-	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June
1505		-	1, 2022.
	1404	+	(3) eluxadoline (5 –[[[(2S)–2–amino–3–[4–aminocarbonyl)–2, 6 –22
	1405	+	dimethylphenyl]–1–oxopropyl][(1S)–1–(4–phenyl–1H–imidazol–2–23
	1406	+	yl)ethyl]amino]methyl]–2–methoxybenzoic acid) (including its optical isomers) and its 24
	1407	+	salts, isomers, and salts of isomers. 25
1506	1408
1507		-	Approved by the Governor, May 12, 2022.
	1409	+	(h) By regulation, the Department may exempt from this section a compound, 26
	1410	+	mixture, or preparation that contains a depressant substance listed in subsection (c) of this 27
	1411	+	section if: 28
	1412	+	30 HOUSE BILL 33
	1413	+
	1414	+
	1415	+	(1) the compound, mixture, or preparation contains an active medicinal 1
	1416	+	ingredient that does not have a depressant effect on the central nervous system; and 2
	1417	+
	1418	+	(2) the admixtures are included in combinations, quantity, proportion, or 3
	1419	+	concentration that vitiate the potential for abuse of the substances that have a depressant 4
	1420	+	effect on the central nervous system. 5
	1421	+
	1422	+	(i)] (B) The Department may not add a substance to Schedule IV under § 6
	1423	+	5–202 of this title unless the Department finds that: 7
	1424	+
	1425	+	(1) the substance has a low potential for abuse relative to the substances 8
	1426	+	listed in Schedule III; 9
	1427	+
	1428	+	(2) the substance has currently accepted medical use in treatment in the 10
	1429	+	United States; and 11
	1430	+
	1431	+	(3) abuse of the substance may lead to limited physical dependence or 12
	1432	+	psychological dependence relative to the substances in Schedule III. 13
	1433	+
	1434	+	5–406. 14
	1435	+
	1436	+	(a) Schedule V consists of each controlled dangerous substance: 15
	1437	+
	1438	+	[(1) listed in this section; 16
	1439	+
	1440	+	(2)] (1) added to Schedule V by the Department under § 5–202(b) of this 17
	1441	+	title; or 18
	1442	+
	1443	+	[(3)] (2) designated as a Schedule V controlled dangerous substance by 19
	1444	+	the federal government unless the Department objects under § 5–202(f) of this title. 20
	1445	+
	1446	+	[(b) Unless specifically excepted or unless listed in another schedule, any material, 21
	1447	+	compound, mixture, or preparation containing any of the following narcotic drugs and their 22
	1448	+	salts, as set forth below: 23
	1449	+
	1450	+	(1) reserved; and 24
	1451	+
	1452	+	(2) reserved. 25
	1453	+
	1454	+	(c) Any compound, mixture, or preparation containing any of the following 26
	1455	+	narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited 27
	1456	+	quantities as set forth below, which shall include one or more nonnarcotic active medicinal 28
	1457	+	ingredients in sufficient proportion to confer upon the compound, mixture, or preparation 29
	1458	+	valuable medicinal qualities other than those possessed by narcotic drugs alone: 30
	1459	+
	1460	+	(1) not more than 200 milligrams of codeine per 100 milliliters or per 100 31
	1461	+	grams; 32 HOUSE BILL 33 31
	1462	+
	1463	+
	1464	+
	1465	+	(2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or 1
	1466	+	per 100 grams; 2
	1467	+
	1468	+	(3) not more than 100 milligrams of ethylmorphine per 100 milliliters or 3
	1469	+	per 100 grams; 4
	1470	+
	1471	+	(4) not more than 2.5 milligrams of diphenoxylate and not less than 25 5
	1472	+	micrograms of atropine sulfate per dosage unit; or 6
	1473	+
	1474	+	(5) difenoxin preparations 0.5mg/25ug ATSO4/DU (MOTOFEN). 7
	1475	+
	1476	+	(d) Unless specifically exempted or excluded or unless listed in another schedule, 8
	1477	+	any material, compound, mixture, or preparation that contains any quantity of the 9
	1478	+	following substances having a stimulant effect on the central nervous system, including its 10
	1479	+	salts, isomers, and salts of isomers: 11
	1480	+
	1481	+	(1) pyrovalerone; and 12
	1482	+
	1483	+	(2) reserved. 13
	1484	+
	1485	+	(e) Unless specifically exempted or excluded or unless listed in another schedule, 14
	1486	+	any material, compound, mixture, or preparation that contains any quantity of the 15
	1487	+	following substances having a depressant effect on the central nervous system, including 16
	1488	+	its salts: 17
	1489	+
	1490	+	(1) brivaracetam ((2S) –2–[(4R)–2–oxo–4–propylpyrrolidin–1–yl] 18
	1491	+	butanamide) (Briviact); 19
	1492	+
	1493	+	(2) ezogabine [N–[2–amino–4–(4–fluorobenzylamino)–phenyl]–carbamic 20
	1494	+	acid ethyl ester] (Potiga); 21
	1495	+
	1496	+	(3) lacosamide [(R)–2–acetoamido–N–benzyl–3–methoxy–propionamide] 22
	1497	+	(Vimpat); and 23
	1498	+
	1499	+	(4) pregabalin [(S)–3–(aminomethyl)–5–methylhexanoic acid] (Lyrica). 24
	1500	+
	1501	+	(f) A drug product in finished dosage formulation that has been approved by the 25
	1502	+	United States Food and Drug Administration that contains cannabidiol (2–[1R–3–methyl–26
	1503	+	6R–(1–methylethenyl)–2–cyclohexen–1–yl]–5–pentyl–1,3–benzenediol) derived from 27
	1504	+	cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols. 28
	1505	+
	1506	+	(g)] (B) The Department may not add a substance to Schedule V under § 5–202 29
	1507	+	of this title unless the Department finds: 30
	1508	+
	1509	+	(1) the substance has a low potential for abuse relative to the substances 31
	1510	+	listed in Schedule IV; 32 32 HOUSE BILL 33
	1511	+
	1512	+
	1513	+
	1514	+	(2) the substance has currently accepted medical use in the United States; 1
	1515	+	and 2
	1516	+
	1517	+	(3) abuse of the substance may lead to limited physical dependence or 3
	1518	+	psychological dependence liability relative to the substances listed in Schedule IV. 4
	1519	+
	1520	+	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June 5
	1521	+	1, 2022. 6
	1522	+
	1523	+
	1524	+
	1525	+	Approved:
	1526	+	________________________________________________________________________________
	1527	+	Governor.
	1528	+	________________________________________________________________________________
	1529	+	Speaker of the House of Delegates.
	1530	+	________________________________________________________________________________
	1531	+	President of the Senate.